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OPTIMAL AND ADAPTIVE DESIGNS FOR MULTI-REGIONAL CLINICAL 
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ABSTRACT 
To shorten the time for drug development and regulatory approval, a growing 
number of clinical trials are being conducted in multiple regions simultaneously. One of 
the challenges to multi-regional clinical trials (MRCT) is how to utilize the data obtained 
from other regions within the entire trial to help make local approval decisions. In 
addition to the global efficacy, the evidence of consistency in treatment effects between 
the local region and the entire trial is usually required for regional approval. In recent 
years, a number of statistical models and consistency criteria have been proposed. The 
sample size requirement for the region of interest was also studied. However, there is no 
specific regional requirement being broadly accepted; sample size planning considering 
regional requirement of all regions of interest is not well developed; how to apply the 
adaptive design to MRCT has not been studied. 
In this dissertation, we have made a number of contributions. First, we propose a 
unified regional requirement for the consistency assessment of MRCT, which generalizes 
the requirements proposed by Ko et al. (2010), Chen et al. (2012) and Tsong et al. (2012), 
  vii 
make recommendations for choosing the value of parameters defining the proposed 
requirement, and determine the sample size increase needed to preserve power. Second, 
we propose two optimal designs for MRCT: minimal total sample size design and 
maximal utility design, which will provide more effective sample size allocation to 
ensure certain overall power and assurance probabilities of all interested regions. We also 
introduce the factors which should be considered in designing MRCT and analyze how 
each factor affects sample size planning. Third, we propose an unblinded region-level 
adaptive design to perform sample size re-estimation and re-allocation at interim based 
on the observed values of each region. We can determine not only whether to stop the 
whole MRCT based on the conditional power, but also whether to stop any individual 
region based on the conditional success rate at interim. The simulation results support 
that the proposed adaptive design has better performance than the classical design in 
terms of overall power and success rate of each region.  
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CHAPTER ONE INTRODUCTION 
 
1.1 Globalization of Drug Development 
There is an increasing trend of globalization of clinical trials - an expansion in 
numbers of both investigators and trials which have been observed outside the United 
States, such as in the European Union, Asia, and Latin America. More clinical trial data 
submitted to the US Food and Drug Administration (FDA) are being collected from 
multiple regions across the world. According to Getz (2007), in an analysis conducted by 
the Tufts Center for the Study of Drug Development, 41% of active FDA regulated 
principal investigators were based outside the United States in 2006. From 2002 to 2007, 
the number of FDA-regulated investigators based outside the United States grew by 15% 
annually, while the U.S.-based investigators declined by 5.5% each year. Table 1.1 shows 
the global distribution of FDA regulated investigators from 1996 to 2006 and respective 
percentage growth in that decade. Central and Eastern Europe (CEE) has been the fastest 
growing region in the world in terms of these investigators. Their investigators numbered 
1793 in 2006 (8% of the total worldwide population) after experiencing a 41% annual 
growth since 1996, when there were only 56 investigators. 
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Table 1.1 Global distribution and growth of FDA regulated investigators from 1996 to 2006 
 1996 Percent of 
Total 
2006 Percent of 
Total 
Annualized 10-year 
Growth Rate 
North America 12,174 83.65% 14,555 63.18% 1.80% 
Western Europe 1899 13.05% 3923 17.03% 7.52% 
Central and Eastern 
Europe 
56 0.38% 1793 7.78% 41.4% 
Latin America 98 0.67% 1095 4.75% 27.3% 
Asia 108 0.74% 1054 4.58% 25.6% 
Rest of World 218 1.50% 617 2.68% 11.0% 
Total 14,757  23,037   
 
1.2 Bridging Studies 
Global drug development with the objective of acquiring regulatory approval 
from multiple regions/countries has been drawing attention from both regulatory agencies 
and pharmaceutical companies in recent years. To facilitate the development and 
registration of new drugs across regions, The International Conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (a.k.a., 
ICH-E5) guideline was issued in 1998. It provided a framework for evaluating the impact 
of ethnic factors on efficacy, safety, and dose–response of drugs based on the concepts of 
“bridging” and “extrapolation” of clinical data from one region to another. This 
minimized unnecessary duplication of clinical trials among the different regions and 
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expedited the availability of new drugs to patients.   
With the implementation of the ICH-E5 guideline, clinical trials bridging foreign 
clinical data to emerging regions, so-called “bridging studies”, have been conducted with 
increasing frequency, especially in Japan. According to Uyama et al. (2005), new drug 
approvals in Japan based upon the “bridging” strategy have been gradually rising, from 
3.2% in 1999 to 25% in 2003. However, “bridging” studies are often conducted after the 
drugs have already been approved in the original region, which usually results in a 
delayed launch of new drugs available to patients in the emerging regions. Figure 1.1 
demonstrates the drug lag in various countries after the drugs were approved in the 
original region for the top 100 best-selling drugs in the world from 2004 to 2007. The 
“drug lag” means, for example, circumstances in which drugs already approved in the 
European Union, the United States or other regions have not yet been approved and have 
not been made available to patients in Japan over a certain period of time.  
 
 
Figure 1.1 Drug lag of various countries for the top 100 best-selling drugs in the world from 2004 to 2007. 
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As illustrated in Figure 1.1, Japan’s approval of the top 100 best-selling drugs is, 
on average, 1,417 days later than their approval in the original regions. The United States 
(USA) has the smallest drug lag across the world - 505 days. Japanese patients have to 
wait nearly 900 days longer than their US counterparts for the ability to use new drugs. 
 
1.3 Multi-Regional Clinical Trials 
In response to the “drug lag” problem in Japan, the Ministry of Health, Labor and 
Welfare (MHLW) issued the “Basic Principles on Global Clinical Trials” guidance 
document in 2007 to streamline and expedite new drug registration in Japan. The 
guidance document provides basic concepts for planning and implementing multi-
regional clinical trials (MRCT) using Q&A format, with one point specifically addressing 
determination of the number of Japanese patients. The term “Multi-Regional Clinical 
Trials” (MRCT) was employed in response to the first question: “I am planning to 
develop my new drug globally. Does ICH E-5 (1998) provide guidance for this approach?” 
in the Q&A section. The ministry did not recommend any single method to determine the 
number of Japanese patients. However, it did provide two examples, called Method 1 and 
Method 2.  
For Method 1, the sample size needed for the Japanese patients in an MRCT was 
to satisfy 
 ( ) 1JP D Dπ β     
where JD  and D  are the observed treatment effects from the group of Japanese patients 
and the entire patient population, respectively, and π , the effect retention rate, 0.5 , β  , 
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the type II error rate, 0.2 . For Method 2, the planned sample size for the Japanese 
group in an MRCT was to satisfy 
1 2( 0, 0, , 0) 1sP D D D       
where 
iD  represents the observed treatment effect for region i, i=1,…,s. Here the s is to 
denote the number of regions. 
1.3.1 Benefits and Challenges of MRCT 
The use of MRCT in drug development will be of great benefit to the creation of 
solid evidence regarding the safety and efficacy of drugs, to more efficient and cost-
effective drug development, and to a resolution of the “drug lag” with simultaneous 
worldwide registration. Despite the benefits, there are also some challenges from 
different aspects: 
 Multiple countries, cultures, medical practices 
 Multiple laws/policies 
 Multiple interpretations/applications of same data 
 Multiple national interests 
 Varying regulatory and scientific capacity 
The MRCT cross-functional key issues team classified these challenges into five 
categories (SCOPE): 
 Statistical 
 Clinical 
 Operational 
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 Regulatory 
 Ethical 
This paper focuses on the statistical challenges of MRCT, and we try to propose the 
solutions to some of statistical challenges listed below:  
 Multi-regional trial versus multiple regional trials 
 Use of placebo / choice of control  
 Power/sample size planning 
 Randomization stratified by region / stratified analysis 
 Drug approved in countries with different dosing regimens 
 Consistency of treatment effect 
 Group sequential and adaptive designs in an MRCT  setting 
 How to describe/present data by region 
 Acceptability of non-inferiority vs. superiority studies – regional acceptability  
 Lack of consensus in terms of the non-inferiority margins  
1.3.2 Assessment of Consistency in Treatment Effect  
There are two objectives in conducting MRCT. On one hand, we need to show the 
global efficacy of a test drug across regions; on the other hand, we need to evaluate if the 
global treatment effect could be applied to each local region. Therefore, the premise of 
conducting MRCT is that we can find some evidence to show little or no regional 
variation. This evidence could be collected from disease knowledge (e.g. epidemiology 
and biology) and early stage data (e.g. non-clinical lab data, pre-clinical animal data and 
7 
 
 
 
early clinical data). If substantial regional differences are anticipated, the drug 
development strategy utilizing MRCT will be less efficient. As demonstrated in Hung 
et.al. (2010), the total sample size would be 3-4 fold higher if the between-region 
variation is 50% of the treatment effect. Thus, the MRCT is not appropriate if between-
region variation is large; multiple regional clinical trials rather than MRCT may be more 
appropriate. Chen et.al (2010) did a systematic review of existing methods that may 
potentially be used for assessing consistent treatment effect across regions. Some of these 
methods were proposed for different purposes, e.g. bridging studies, meta-analysis, etc. 
These methods were classified into three groups.  
1. Global Methods, which are based on one single global statistic combining data 
across all regions. The commonly used treatment-by-region interaction tests are 
included in this group. In addition, the non-parametric quantitative interaction 
tests (e.g. Cochran’s Q, Breslow-Day, etc.) and quantifying heterogeneity tests 
(Higgin’s 2I ) are also in this group.  
2. Multivariate Quantitative Methods, which assess the quantitative differences 
among regions simultaneously. Consistency is concluded if all pairwise 
differences between regions are within pre-specified bounds, i.e. 
{| | ;for , 1, , }i j ijD D b i j s     
3. Multivariate Qualitative Methods, which assess the qualitative differences 
among regions simultaneously. Consistency is concluded if all point estimates 
from individual regions are better than corresponding thresholds i.e. 
{ ;for all 1, , }i iD D c i s    . The two PMDA methods are included in this 
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group. 
In addition to these methods, Chen et al. (2013) proposed the graphical tools to facilitate 
identification of potential outlying countries for country-level assessment. They applied 
normal probability plots, which are commonly used as a diagnostic tool in linear 
regression analysis, to assess the differences among countries. 
1.3.3 Statistical Models for MRCT 
Quan et al. (2010) proposed the fixed effects model for MRCT and also derived 
closed-form for the sample size calculation for normal, binary and survival endpoint 
based on Method 1. Hung et al. (2010) raised the concern that the fixed effects model 
may not be appropriate for MRCT, providing insightful examples to illustrate potential 
problems of an MRCT design when the regional effects are different. Quan et al. (2012) 
proposed the empirical shrinkage estimation approach based on the random effects model 
to assess the consistency of treatment effect across regions, which presumably could help 
obtain better consistency compared to the fixed effects model. Lan and Pinheiro (2012) 
proposed the discrete random effects model to combine the treatment effect estimates 
from individual sources of data, e.g., regions, trials; detailed applications to MRCT and 
meta-analysis are also presented. Lan et al. (2014) further elucidate the application of the 
discrete random effects model to time-to-event and binary response. They also provided 
some guidelines on how to design MRCT using the discrete random effects model. The 
comparisons of these three models are listed in Table 1.3. 
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Table 1.2 Comparisons of the three models for MRCT 
Model 
iN  i  Overall 
Estimator 
Expectation 
Fixed effects 
model 
Fixed Parameter Dˆ  
1ˆ( )
s
i ii
n
E D
N



 
Random effects 
model 
Fixed Random ˆ  ,D D  ˆ( ) ( )E D E D    
Discrete random 
effects model 
Random 
( , )iMN N w  
Parameter Dˆ  
1
1
ˆ( )
s
i ii
s
i ii
n
E D
N
w








 
 
1.4 Bridging Studies vs. MRCT in Statistical Efficiency 
The bridging strategy is a step-wise drug development approach while the MRCT 
is a one-step approach. Heterogeneity among studies, which is also called between study 
variability, is often observed in drug development. Heterogeneity may be due to 
differences in study conduct, lag in time, etc. Chen et al. (2012) presented the current 
practice of bridging studies and MRCT in China; they mentioned that the study design for 
the post-market studies, i.e. bridging studies for many of the drug products, were not the 
same as the global premarket clinical studies in terms of control group and study endpoint. 
This makes it impossible to directly compare the results from the pre- and post-market 
studies for such cases. Because of heterogeneity, the bridging strategy may be less 
efficient in showing consistency than the global strategy. Li et al. (2013) compared the 
statistical efficiency in demonstrating consistency effect in the region of interest. They 
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found that the MRCT has a substantially higher probability to show consistency effect 
than the bridging strategy even with small between-study variability, as illustrated in 
Figure 1.2. The value of   represents the ratio of between-study to between-patient 
variances. If there is no between study variance, i.e. 0  , it is corresponding to MRCT; 
otherwise, it is corresponding to the bridging strategy, i.e. 0.001, 0.01, 0.03  . 
 
 
Figure 1.2 Comparison in statistical efficiency between bridging studies and MRCT 
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1.5 Structure of the Dissertation 
In this dissertation we develop a unified consistency requirement in consideration 
of regional approval for MRCT; in addition, we propose two optimal sample size 
allocation designs and one adaptive design. 
In Chapter 2, we propose a unified consistency requirement for regional approval 
using a hypothesis test to examine whether the overall results can be applied to a specific 
region. First we assess the sample size needed to achieve certain assurance probability for 
all regions of interest with 0.5π   in Method 1 for different numbers of regions, and 
compare our results with those calculated by the traditional method. Second we 
demonstrate an approach to determine the parameters ( , )iπ α  in consideration of practical 
usage, and finally recommend some pairs for different numbers of regions. After that we 
introduce the assurance probability curve, which could be used to evaluate the 
performance of the different combinations of parameters in the consistency requirement. 
Finally, we use examples to illustrate the practical application of the proposed methods.  
In Chapter 3, we introduce two optimal sample size allocation designs for MRCT, 
i.e. minimal total sample size design and maximal utility design. First, we introduce the 
five factors which should be taken into consideration when designing MRCT. Second we 
discuss how each factor affects the sample size planning of MRCT. After that, we use 
hypothetical examples to illustrate how to design the MRCT using the proposed optimal 
designs as well as taking all the factors into consideration. In the end, we provide detailed 
conclusion and discussion in regards to the optimal designs. 
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In Chapter 4, we introduce a region-level adaptive design for MRCT. First we 
introduce the statistical framework for the adaptive design, including the test statistic of 
each stage, conditional power, conditional assurance probability and conditional success 
rate. Second, a detailed step-by-step demonstration of the adaptive design will be 
introduced, including the initial sample size planning, adaptation strategies at interim and 
the final decision rules for the entire MRCT and each region. After that, we compare the 
adaptive design with the classical design in terms of overall power, success rate of each 
region and average sample size; we also demonstrate that the type I error rate will be 
controlled when selecting the stopping boundaries appropriately. In the end, we provide a 
detailed conclusion and discussion of our methods. 
In Chapter 5, we provide concluding remarks and discuss the possibilities of 
extending the proposed methodologies in Chapters 2, 3 and 4 to binary and survival 
endpoint.  
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CHAPTER TWO 
UNIFIED CONSISTENCY REQUIREMENT IN CONSIDERATION OF 
REGIONAL APPROVAL FOR MULTI-REGIONAL CLINICAL TRIALS 
 
2.1 Introduction 
For the purpose of reducing the cost and time in developing new drugs, more and 
more clinical trials are being conducted in multiple regions simultaneously. One of the 
statistical challenges in conducting multi-regional clinical trials (MRCT) is how to apply 
the overall efficacy findings to the regions of interest.  
To evaluate the possibility of applying the overall results in an MRCT to the 
specific regions of interest, the Japanese Ministry of Health, Labor and Welfare (MHLW) 
proposed two methods for determining the needed number of Japanese subjects for 
establishing consistency of the treatment effect between Japanese patients and others. 
Based on the Japanese MHLW guidance, a number of consistency criteria were proposed 
to evaluate if the overall results of an MRCT can be applied to specific region(s). On the 
basis of Method 2, Kawai et al. (2008) proposed an approach to partition the total sample 
size to the individual regions to ensure a high probability of observing a consistent trend 
if the treatment effect is positive and uniform across the regions. On the basis of Method 
1, Quan et al. (2010) discussed the sample size requirement for normal, binary and 
survival endpoint. Quan et al. (2010) proposed five definitions of consistency, and 
calculated the probability of consistency for different configurations of sample size 
allocations and true treatment effects in individual regions. Ko et al. (2010) proposed four 
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criteria to determine whether the treatment is effective in a specific region given the 
overall result is significant at the α  level. Tsong et al. (2012) then proposed an approach 
to control the type I error rate of a specific region adjusted for the regional sample size. In 
particular, what they proposed was to determine the sample size of an MRCT to 
accommodate the overall type I error rate as well as the regional specific type I error rate. 
Chen et al. (2012) proposed two conditional decision rules for regional approval, where 
sample size determination and the relationship between the two rules were also discussed. 
Quan et al. (2012) proposed the empirical shrinkage estimation approach based on the 
random effects model to assess the consistency of treatment effect across regions, which 
presumably could help obtain better consistency compared to the fixed effects model. 
Tsou et al. (2012) also proposed a consistency criterion to examine whether the overall 
results can be applied to all participating regions; sample size requirement was also 
discussed.  
It should be noted that most available approaches for MRCT imposed a common 
criterion to assess the consistency in all regions regardless of the number of regions 
included in an MRCT. For example, in Method 1, the rate of retention of the overall 
treatment effect, i.e.,π  was set as a fixed value. When more and more regions are 
included in an MRCT, huge samples will be needed to preserve a certain power and 
probability for the consideration of regional approval. Some calculations have shown that 
the sample size needed will double or triple that of the original size in a traditional design 
even when π  is only 0.5. To avoid this happening, the value of π  should be carefully 
chosen. One approach to determine π  is to tie it with the number of regions. In particular, 
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we propose to adopt different consistency requirements, e.g. different retention rates π  
for different numbers of regions to evaluate if the treatment is effective in each region 
when the overall treatment effect is significant.  
We organize this chapter as follows. In section 2.2, we propose a unified 
consistency requirement for regional approval using hypothesis test to examine whether 
the overall results can be applied to a specific region. In section 2.3, we assess the sample 
size needed to achieve certain assurance probability for all regions of interest with 
0.5   in Method 1 for different numbers of regions, and compare our results with those 
calculated by the traditional method. In section 2.4, we further demonstrate an approach 
to determine the parameters ( , )i   in consideration of practical usage, and finally 
recommend some pairs for different numbers of regions. In section 2.5, we use the 
proposed assurance probability curve to evaluate the performance of the different 
combinations of parameters in the consistency requirement. In section 2.6, we use 
examples to illustrate the practical application of the proposed method. Finally, we 
provide a detailed conclusion and discussion of our method in section 2.7. 
 
2.2 Unified Consistency Requirement for Regional Approval 
For simplicity, we only focus on the trials with a test drug and a placebo control. 
We also consider a continuous endpoint in assessing the treatment efficacy. Assume that 
Tμ  and Pμ  are the population means for test drug and placebo control, and 
2σ  is the 
variance for patients who are in either test drug or control group. We also denote 
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T P μ μ μ  the difference of population means. The hypothesis for testing the overall 
treatment effect is given as   
 1 1
0 : 0 versus : 0aH H     
We denote N  the total sample size needed for a trial to detect the expected 
treatment difference μ  at a desired one-sided significance level of α  and 1   power. 
Using a two sample t-test, it is clear that  
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where 1z α  is the (1 ) thα  percentile of the standard normal distribution.  
Let i Ti Pi μ μ μ  be the true mean difference for regions i,
2
iσ  the variance for 
patients in region i. Although 2
iσ  can be different across regions, in this section, we 
assume that 2
iσ  are known and the same for all regions, namely,
2 2 , 1, , .i i s σ σ
Assume that iD  is the observed mean difference for region i and in  is the number of 
patients in each arm of region i, icD  is the observed mean difference for regions other 
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where if  is the proportion of patients in the ith region,
1
1, , 1.
s
i
i
i s f

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Given that the overall result is significant at α  level, one criterion used to 
determine whether the treatment is effective in the ith region is as follows:  
 iD Dπ   (2.2) 
where iD  and D  are the “observed” treatment effects for the region of interest and the 
entire group. Note that the consistency between the region of interest and the entire group 
has been tested based on only the “observed” treatment effects even though the purpose 
of the regional requirement should test the consistency of the “true” treatment effect, not 
the “observed” treatment effect. Thus, we propose the following hypothesis test for 
ensuring consistency based on “true” treatment effect as a new consistency requirement: 
 2 2
0 : versus :i a iH H μ πμ μ πμ   (2.3) 
When 2
0H  is rejected, we can claim that the treatment effect in region i is consistent with 
the entire group, although one should note that using the same retention rate, i.e.π  
considered, it will be more difficult to claim consistency by (2.3) if the one-sided 
significance level 0.5i α  compared to (2.2), which has been noted in Quan et al. (2010). 
We denote the test statistics by Z  and iZ  for the overall efficacy 
1( )H  and the 
consistency requirement for region i 
2( )H , respectively.  
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The corresponding unconditional and conditional probabilities of rejection become, 
respectively, 
 
1( )iiP Z zμ α   (2.6) 
and 
 
1 1( | )iiP Z z Z zμ α α     (2.7) 
The above conditional probability (2.7) is our focus and we define it as assurance 
probability (AP). The mathematical derivations of (2.7) are given below. 
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Note that when 0.5i α , i.e. 1 0iz  α , iAP  in formula (2.7) is reduced to
1( | )iP D D Z z  μ απ which is equivalent to the criteria described as “Criteria II” in Ko 
et al. (2010) and “CDR 1”in Chen et al. (2012). We denote the assurance probability of 
this special case as 1
iAP . That is 
 1
1( | )i iAP P D D Z z   μ απ   (2.8) 
In addition, when 0π , iAP  in formula (2.7) is reduced to 1 1( | )
( ) i
i
i
D
P z Z z
std D
  μ α α =
1 1( | )iiP Z z Z z 
  μ α α , where iZ   is the test statistic of the following hypothesis test: 
 3 3
0 : 0 versus : 0i a iH H μ μ   (2.9) 
Note that (2.9) is to examine whether the treatment is effective in region i at the iα  level, 
in which case we adopted a similar concept to the method proposed in Tsong et al. (2012) 
and “CDR 2”in Chen et al. (2012). We denote the assurance probability of this special 
case as 2
iAP . That is 
 2
1 1( | )ii iAP P Z z Z z 
  μ α α   (2.10) 
Thus, 1
iAP  in (2.8) and 
2
iAP  in (2.10) are the special cases of the defined assurance 
probability in (2.7).  
 
2.3 Sample Size for Achieving Certain Assurance Probability with (𝝅, 𝜶𝒊) = (0.5, 0.5)  
In the next two sections, we assume that the treatment effect are uniform across 
regions and the total sample size is evenly distributed to each region; namely, 
, 1/ , 1, , .i if s i s  μ μ   
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In this section, we consider 0.5i α , which is a special case of 
2
iAP  in terms of 
assurance probability. We first compare the sample size needed to achieve certain 
assurance probability for this special case with that for (2.1). Assume we increase the 
total sample size to ρ -fold the sample size calculated by the traditional method:
* , 1N N ρ ρ , then under these assumptions, 1
iAP  can be calculated via formula (2.11):  
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By considering 0.025, 0.2, 0.5, 0.5i   α β π α , and s between 2 to 6, the 
sample size 
* /N Nρ  to achieve the desired assurance probability at different levels of 
0.80, 0.85, and 0.90, respectively, can be obtained via formula (2.11) using numerical 
methods. Here, N  is the total sample size needed to achieve 80% power at a one-sided 
significance level of 0.025 when not considering the consistency requirement for regional 
approval; 
*N is the sample size needed to achieve 80% power and the desired assurance 
probability of each region when considering the consistency requirement for regional 
approval.  
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Table 2.1 Sample size requirement to achieve certain assurance probability (80%, 85% and 90%) 
* /N Nρ  
AP s=2 s=3 s=4 s=5 s=6 
0.8 1 1 1 1.35 1.81 
0.85 1 1 1.66 2.29 2.87 
0.9 1 1.77 2.70 3.56 4.40 
 
Table 2.1 displays the sample size to achieve certain assurance probability. As 
illustrated in Table 2.1, the larger the desired assurance probability is as well as the more 
regions an MRCT includes, the larger of a sample size is needed. For example, no sample 
size increase is necessary to achieve 90% assurance probability if an MRCT only 
contains two regions and the samples are evenly allocated to the two regions. However, it 
leads to a 170% sample size increase if an MRCT contains four regions.  
So far, we have only considered that the posited means and variances of the 
treatment effect are uniform across regions. It is certainly reasonable to expect a much 
larger sample size when the treatment effect of the region of interest is smaller than the 
other regions or its variance is larger than the others, or when its sample size fraction is 
smaller than the average. Thus, in order to avoid the need of consuming huge samples for 
an MRCT trial by preserving certain assurance probability for the regions of interest, we 
consider the combination of ( , )iπ α  depending on the number of regions. The details of 
our method are explained in the next section. 
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2.4 Determination of 𝝅 and 𝜶𝒊 for Different Numbers of Regions  
As illustrated in section 2.3, more samples will be needed if more regions are 
included in an MRCT when a fixed treatment effect retention rate, i.e.π , is considered, 
although a huge sample size increase may not be plausible for an MRCT trial. In order to 
conquer this challenge, we need to choose the appropriate values of π  and iα  for 
different numbers of regions.  
For the purpose of illustration, we determine the combinations of ( , )iπ α  using 
numerical methods to achieve 80% and 90% assurance probability respectively for 
different sample size configurations, i.e., 1.0,1.5 and 2.0ρ , given that the sample size 
would not exceed 2-fold the sample size calculated by (2.1). We can easily extend the 
sample size to any fold and to reach any desired assurance probability. We first start by 
determining the combinations of ( , )iπ α  in the two aforementioned special cases (i.e. 1. 
Determine the value of π  for 0.5i α ; the assurance probability is corresponding to
1
iAP ; 
2. Determine the value of iα  for 0π ; the assurance probability is corresponding to
2
iAP ), and then we further determine the general combinations of ( , )iπ α  to achieve the 
same level of assurance probability. Tables 2.2-2.8 exhibit the combinations of ( , )iπ α  
which achieve 80% and 90% assurance probability respectively under different sample 
size configurations, i.e. 1.0,1.5 and 2.0  for different numbers of regions.  
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Table 2.2 Determination of the value of 𝝅 for 𝜶𝒊 = 𝟎. 𝟓 under different configurations of 𝛒 and different 
numbers of regions. 
  when 0.5i π α  
 ρ  s=2 s=3 s=4 s=5 s=6 
1 0.8iAP   1 0.727 0.614 0.527 0.454 0.389 
1.5 0.759 0.659 0.583 0.518 0.462 
2 0.786 0.697 0.629 0.572 0.522 
1 0.9iAP   1 0.573 0.396 0.260 0.146 0.045 
1.5 0.623 0.466 0.347 0.246 0.157 
2 0.665 0.527 0.420 0.331 0.252 
 
Table 2.2 demonstrates the value of π  when 0.5i α  to achieve 80% and 90% 
assurance probability respectively for the number of regions between 2 and 6. For 
example, when the total sample size is 1.5-fold the original sample size, the value of π  to 
achieve 80% assurance probability is 0.583 for an MRCT including four regions. Note 
that the value of π  was obtained via formula (2.7) using numerical methods since there 
is no closed-form solution for π . By observing Table 2.2, we can also locate a 
reasonable range of the value of π  for different numbers of regions. Considering four 
regions and 80% assurance probability, the reasonable value of π  should be between 
0.527 and 0.629 if the expected total sample size does not exceed 2-fold the original 
sample size. If the value of π  is much smaller than 0.527, the proposed consistency 
requirement may be too loose. On the other hand, if the value of π  is greater than 0.629, 
25 
 
 
 
it will require more than a 2-fold sample size to preserve 80% assurance probability. 
When we do not expect a sample size increase, i.e., 1ρ , the value of π  should be 
between 0.26 and 0.527 for four regions in order to achieve the assurance probability of 
80- 90%. 
 
Table 2.3 Determination of the value of 𝜶𝒊 for 𝛑 = 𝟎 under different configurations of 𝝆 and different number of 
regions. 
  when 0i α π  
 ρ  s=2 s=3 s=4 s=5 s=6 
2 0.8iAP   1 0.071 0.151 0.219 0.274 0.318 
1.5 0.042 0.106 0.167 0.219 0.264 
2 0.022 0.069 0.120 0.168 0.211 
2 0.9iAP   1 0.135 0.262 0.357 0.427 0.479 
1.5 0.091 0.201 0.292 0.363 0.419 
2 0.055 0.144 0.228 0.298 0.356 
 
Table 2.3 demonstrates the value of iα  when 0π  to achieve 80% and 90% 
assurance probability respectively for the number of regions between 2 and 6. For 
example, when the total sample size is 1.5-fold the original sample size, the value of iα  
to achieve 80% assurance probability is 0.167 for an MRCT including four regions. 
Similar to Table 2.2 the value of iα  was also obtained in terms of numerical method. By 
observing Table 2.3, we can also locate a reasonable range of the value of iα  for different 
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numbers of regions. Considering four regions and 80% assurance probability, the 
reasonable value of iα  should be between 0.12 and 0.219 if the expected total sample size 
does not exceed 2-fold the original sample size. If the value of iα  is much greater than 
0.219, the consistency requirement may be too loose. On the other hand, if the value of 
iα  is smaller than 0.12, it will require more than a 2-fold sample size to preserve 80% 
assurance probability. When we do not expect a sample size increase, i.e., 1ρ , the value 
of iα  should be between 0.219 and 0.357 for four regions in order to achieve the 
assurance probability of 80-90%. 
As illustrated in the above two cases, using the formula of (2.7), we can find the 
corresponding value of π  for any given iα  or find the corresponding value of iα  for any 
given π  to achieve a given assurance probability. Tables 2.4-2.8 demonstrate the set of 
( , )iπ α  which achieve 80% and 90% assurance probability for the number of regions 
between 2 and 6. Since we have set a fixed assurance probability, i.e. 80% or 90% for 
any combination of ( , )iπ α  in Tables 2.4-2.8, it is not surprising to observe a trade-off 
between and iπ α : for a fixed ρ , when π increases, iα also increases.  
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Table 2.4 Determination of the values of 𝜶𝒊 for different values of 𝛑 for an MRCT including two regions (s=2)  
s=2:  
iα  
 ρ  0π  0.1π  0.3π  0.5π  0.7π  
0.8iAP   1 0.071 0.090 0.154 0.274 0.469 
1.5 0.042 0.057 0.108 0.219 0.424 
2 0.022 0.032 0.071 0.168 0.376 
0.9iAP   1 0.135 0.168 0.267 0.427 >0.5 
1.5 0.091 0.118 0.205 0.363 >0.5 
2 0.055 0.075 0.148 0.298 >0.5 
 
Table 2.5 Determination of the values of 𝜶𝒊 for different values of 𝝅 for an MRCT including three regions (s=3) 
s=3:  
iα  
 ρ  0π  0.1π  0.3π  0.5π  0.6π  
0.8iAP   1 0.151 0.184 0.278 0.410 0.489 
1.5 0.106 0.135 0.223 0.360 0.445 
2 0.069 0.093 0.172 0.308 0.400 
0.9iAP   1 0.262 0.310 0.432 >0.5 >0.5 
1.5 0.201 0.246 0.368 >0.5 >0.5 
2 0.144 0.185 0.303 0.474 >0.5 
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Table 2.6 Determination of the values of 𝜶𝒊 for different values of 𝝅 for an MRCT including four regions (s=4) 
s=4:  
iα  
 ρ  0π  0.1π  0.3π  0.5π  
0.8iAP   1 0.219 0.259 0.359 0.482 
1.5 0.167 0.205 0.305 0.438 
2 0.120 0.155 0.252 0.392 
0.9iAP   1 0.357 0.408 >0.5 >0.5 
1.5 0.292 0.344 0.468 >0.5 
2 0.228 0.279 0.408 >0.5 
 
Table 2.7 Determination of the values of 𝛂𝐢 for different values of 𝝅 for an MRCT including five regions (s=5) 
s=5:  
iα  
 ρ  0π  0.1π  0.3π  0.4π  
0.8iAP   1 0.274 0.316 0.414 0.469 
1.5 0.219 0.261 0.364 0.424 
2 0.168 0.208 0.313 0.376 
0.9iAP   1 0.427 0.477 >0.5 >0.5 
1.5 0.363 0.416 >0.5 >0.5 
2 0.298 0.352 0.449 >0.5 
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Table 2.8 Determination of the values of 𝜶𝒊 for different values of 𝝅 for an MRCT including six regions (s=6)  
s=6:  
iα  
 ρ  0π  0.1π  0.3π  
0.8iAP   1 0.318 0.360 0.455 
1.5 0.264 0.307 0.407 
2 0.211 0.254 0.359 
0.9iAP   1 0.479 >0.5 >0.5 
1.5 0.419 0.470 >0.5 
2 0.356 0.410 >0.5 
 
Finally, considering a practical sample size increase we recommend the 
combinations of ( , )iπ α  for the number of regions from two to six which are listed in 
Table 2.9. These pairs give each region at least 80% assurance probability without 
sample size increase ( 1)ρ  under the ideal settings: mean and variance of treatment 
effects are uniform across regions and the samples are evenly allocated to each region. 
The assurance probability will be approximately 85% and 90% for each region with 1.5- 
and 2-fold original sample size, respectively, as illustrated in Figure 2.1 for four regions. 
This method essentially provides a relatively fair consistency requirement for different 
numbers of regions. 
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Table 2.9 Recommendations of (𝝅, 𝜶𝒊) in consideration of number of regions and sample size increase 
( , )iπ α  
s=2 s=3 s=4 s=5 s=6 
(0,0.075) (0,0.15) (0.0,0.225) (0,0.275) (0,0.325) 
(0.1,0.10) (0.1,0.20) (0.1,0.275) (0.1,0.325) (0.1,0.375) 
(0.3,0.175) (0.3,0.30) (0.3,0.375) (0.3,0.45) (0.325,0.5) 
(0.5,0.30) (0.5,0.425) (0.5,0.5) (0.4,0.5) 
 
(0.7,0.5) (0.575,0.5) 
   
 
2.5 Evaluation of Consistency Requirements: Assurance Probability Curve 
In the previous two sections, we determined the combination of ( , )iπ α  given the 
desired total sample size ( * )Nρ , number of regions (s) and assurance probability for the 
case that the regions have uniform mean and variance. Nevertheless, the assumption of 
uniform treatment effect across regions may not hold. When the true treatment effect in 
region i is smaller than the other regions, i.e., *i μ λμ , where 1λ , 
* is the true 
treatment effect for other regions, the assurance probability under this setting becomes 
the following:  
 * *
1 1( | , , 1, 0, )ii i i jP Z z Z z j i        μ α αγ μ λμ λ μ μ   (2.12) 
Here iZ  and Z  are defined in (2.4) and (2.5). Assume we increase the total sample size to
ρ -fold the sample size calculated by the traditional method: * , 1N N ρ ρ , then iγ  
under equal sample size allocation can be calculated as follows: 
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When there is no treatment effect in region i: 0i μ and all other treatment effects 
are the same, i.e., * 0j  μ μ , we then interpret the assurance probability under this 
setting to be the probability of falsely claiming regional approval (PFCRA), which is also 
mentioned in Chen et al.(2012). We define the following probability as PFCRA for 
region i: 
 0 *
1 1( | , 0, 0, )ii i i jP Z z Z z j i       μ α αγ μ μ μ   (2.13) 
Note that since the total sample size we considered earlier in the planning stage was 
based on * 0i  μ μ , it is clear that, when 
*
i μ λμ , where 1λ , the test is likely to be 
underpowered.  
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The ideal consistency requirement should anticipate the assurance probability ( )iγ    
close to 0 when there is no treatment effect in this region, i.e., λ  is around 0 or smaller 
than 0, whereas it is close to 1 when the regional treatment effect is consistent with the 
overall result or better than the overall treatment effect, i.e., λ  is around 1 or greater than 
1. Take four regions as an example, Figure 2.1 demonstrates the assurance probabilities
( )iγ  with different values of λ  in (2.12) for the recommended combinations of ( , )iπ α  
with original sample size, 1.5- and 2-fold sample size, respectively.  
 
Figure 2.1 Assurance probability curves for an MRCT including four regions with different sample size 
When 0λ , the assurance probability is interpreted as the PFCRA, the assurance 
probability when 1λ  is the probability of showing consistency of regional treatment 
effect with the overall results when the treatment effect are uniform across regions. The 
curves in the three plots of Figure 2.1 are almost parallel for all parameter combinations 
of ( , )iπ α , and for this reason we can make the conclusion that there is no optimal 
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parameter combination in the unified consistency requirement. The sample assurance 
probability curve of the ideal consistency requirement is also highlighted by the bold 
black curve in Figure 2.1, which has smaller assurance probability when λ  is small, but 
larger assurance probability when λ  is large compared to other curves. As illustrated in 
Figure 2.1, the assurance probability curves of the recommended parameters are close to 
the ideal assurance probability curve with the sample size increased. If we compare the 
plot of 1  with the plot of 2 , the red curve (corresponding to ( , ) (0,0.225)i π α ) 
lies below other curves in the plot of 1ρ , whereas it lies above other curves in the plot 
of 2ρ (overlap the blue curve), indicating that the special case with 0π  is more 
easily affected by sample size increase. 
 
Figure 2.2 The PFCRA and assurance probability with sample size increase for an MRCT including four 
regions 
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Different recommended combinations of ( , )iπ α  may have different performance 
in terms of PFCRA and assurance probability (when λ = 1) with sample size increase. 
The ideal combination of ( , )iπ α  will make PFCRA decrease quickly, and assurance 
probability (when 1λ ) increase quickly with sample size increase. Take four regions as 
an example: as illustrated in Figure 2.2, the PFCRA corresponding to the combination (0, 
0.225) decreases more slowly than other combinations, but the assurance probability 
increases faster than other combinations with sample size increase. In contrast, the 
PFCRA corresponding to the combination (0.5, 0.5) decreases faster than other 
combinations, but the assurance probability increases more slowly than other 
combinations with sample size increase. For this reason, we can reach the same 
conclusion as before that there is no optimal parameter combination in the unified 
consistency requirement. Thus, we may prefer the general case e.g., (0.3, 0.375) by 
considering both PFCRA and assurance probability (when 1λ ) even though there is no 
optimal combination among all the pairs. 
 
2.6 Hypothetical Examples 
In this section, we provide examples to illustrate the practical applications of our 
method. Assume that we conduct a randomized, double-blinded, active-control MRCT in 
patients from 3 regions: Japan (JP), the European Union (EU) and the United States (US). 
The total sample size is calculated based on the assumptions of overall treatment effect:
5μ  and standard derivation: 21.86σ . In order to achieve 80% power at one-sided 
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significance level 0.025α , the total sample size needed is 300pts/arm. Since the 
sponsor can only afford 30% ( 1.3)ρ  sample size increase besides 300pts/arm due to 
budget limitations, they finally decided to plan MRCT with total sample size of 
390pts/arm.  
Table 2.10 Assurance probability of each region for different configurations of treatment effects and sample size 
allocations 
jpμ   euμ  usμ  jpf   euf  usf  , )iπ α   AP_JP AP_EU AP_US 
5 5 5 0.33 0.33 0.33 (0,0.15) 0.836 0.836 0.836 
Power=0.891 (0.3,0.3) 0.845 0.845 0.845 
      
(0.575,0.5) 0.839 0.839 0.839 
5 5 5 0.1 0.3 0.6 (0,0.15) 0.515 0.806 0.968 
Power=0.891 (0.3,0.3) 0.6 0.82 0.968 
      
(0.575,0.5) 0.684 0.822 0.949 
4 7 7 0.33 0.33 0.33 (0,0.15) 0.686 0.949 0.949 
Power=0.969 (0.3,0.3) 0.656 0.95 0.95 
      
(0.575,0.5) 0.602 0.941 0.941 
4 7 7 0.5 0.25 0.25 (0,0.15) 0.816 0.903 0.903 
Power=0.940 (0.3,0.3) 0.789 0.916 0.916 
      
(0.575,0.5) 0.708 0.921 0.921 
4 7 7 0.1 0.45 0.45 (0,0.15) 0.413 0.979 0.979 
Power=0.990 (0.3,0.3) 0.458 0.975 0.975 
      
(0.575,0.5) 0.514 0.957 0.957 
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Table 2.10 demonstrates the assurance probability of each region for different 
configurations of true treatment effects and sample size allocations. As illustrated in 
Table 2.10, the best sample size allocation strategy is to allocate samples to each region 
evenly when the true treatment effect is the same as the assumed value of 5 for each 
region. The assurance probability of each region with a total sample size of 390pts/arm is 
around 0.84 for all three combinations of , )iπ α . The second scenario indicates that the 
combination (0, 0.15) is more sensitive to sample size increase. The assurance probability 
changes from 0.515 to 0.968 as sample size increases from 10% to 60%, whereas the 
assurance probability corresponding to combination (0.575, 0.5) only changes from 0.684 
to 0.949.  
If the true treatment effects are not the same across the regions, i.e. scenarios 3-5, 
the equal sample size allocation may not be the best. If we compare scenarios 3-5 in 
terms of overall power and assurance probability of each region, the sample size 
allocation strategy of scenario 4 may be the best choice among these three. First, the 
overall power of 94% is relatively large although it is smaller than in scenarios 3 and 5. 
Second, if we are interested in getting the drug approved in all three regions, scenario 4 
provides more balanced assurance probabilities among the regions than scenarios 3 and 5. 
All the assurance probabilities in scenario 4 are above 0.70 no matter which regional 
requirements are imposed, nevertheless, the assurance probability in scenario 5 could be 
as low as 0.413 when small samples (10%) are allocated to the region with smallest 
treatment effect. Scenarios 3-5 also demonstrate that it is easier to achieve higher 
assurance probability by combination (0, 0.15) with appropriate sample size allocation 
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when the treatment effects are significantly large, but not consistent. When a small 
proportion of samples are allocated to a region with smaller treatment effect, it will result 
in a low assurance probability for this region and large overall power. Even though large 
overall power is guaranteed, this will not help for regional approval because of low 
assurance probability in this region. Thus, the trade-off between overall power and 
assurance probability of each region always plays a role in designing MRCT, so the 
optimal designs of MRCT should balance both. 
 
2.7 Conclusion and Discussion 
Usually, there are two main objectives in conducting an MRCT. The first one is to 
evaluate the overall efficacy of a drug in the global setting and the second is to explore 
the possibility of applying the overall result to some specific regions of interest. In this 
chapter, we perform a hypothesis test to examine whether the overall efficacy results 
from the MRCT can be applied to a region of interest. Although this consistency 
requirement is similar to the method described as “Definition 3” in Quan et al. (2010), 
Quan et al. (2010) applied the criterion to all regions simultaneously. We impose the 
consistency requirement to each region separately by determining the parameters , )iπ α  
simultaneously to meet the regional approval with desired assurance. In particular, we 
take the number of regions into consideration for determining the parameters. We prove 
that the proposed unified consistency requirement generalizes those proposed by Ko et al. 
(2010), Chen et al. (2012) and Tsong et al. (2012).  
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Under the ideal setting (i.e., mean and variance of treatment effects are uniform 
across the regions and the samples are evenly allocated to each region), we calculate the 
required number of samples to achieve a certain level of assurance probability for all 
regions. As illustrated in Table 2.1, a larger sample size is needed to achieve a certain 
level of assurance probability (80%-90%) when an MRCT includes more regions for the 
fixed consistency requirement. In order to conquer the challenge of huge sample size 
increase to achieve certain assurance probability (80%-90%), we tie the parameters 
, )iπ α  in the consistency requirement to the number of regions. The recommended pairs 
of parameters listed in Table 2.9 were determined to achieve at least 80% assurance 
probability with the original sample size of 80% power for the number of regions from 2 
to 6. Our method provides a relatively fair consistency requirement for different numbers 
of regions. The assurance probability will be approximately 85% and 90% when the 
sample size is increased to 1.5- and 2- fold, respectively. Thus, using the recommended 
consistency requirement, we can achieve an acceptable assurance probability for each 
region with affordable sample size increases as long as the MRCT is not extremely 
unbalanced, such as the second and fifth scenarios in Table 2.10.  
One technical issue of the proposed method is that the definition of region in 
MRCT is still not well-delineated. Currently, the regions are simply defined 
geographically; nevertheless, different factors can be taken into consideration in defining 
region, such as therapeutic area or disease state. In practice, unless the regional effect is 
included in the final analysis model, they are seldom pre-defined and so post-hoc 
definitions are more common. To control the overall type I error rate, whereas the regions 
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should be defined in advance, and then the proposed methods could be utilized 
appropriately.  
The other technical issue is how to count the number of regions for the 
consistency requirement. In practice, it is not uncommon to encounter extremely 
unbalanced regions with small sample size proportions in some regions, which could be 
due to the disease prevalence difference or regulatory considerations. Since the 
recommended consistency requirement depends on the number of regions, how to count 
the number of regions plays an important role in the proposed method. If an MRCT only 
has small samples recruited from one region, e.g. <5%, we can impose a loose regional 
requirement for each region. In order to deal with this situation, we propose the following 
criterion to count the number of regions for the consistency requirement so that we can 
determine which pairs of , )iπ α  to adopt when designing MRCT. Denote s  and 0s  the 
number of regions in MRCT and the number of region for the consistency requirement, 
respectively. We define 0s  as the number of regions in which the sample size proportion 
is greater than certain threshold, e.g. 0s  is the number of regions satisfying
1
, 1, ,
3
if i s
s
   . For instance, 0s  is the number of regions with sample size proportion
1
8.3%
3*4
if    if an MRCT includes 4 regions (s=4).  
The recommended pairs of , )iπ α  in Table 2.9 were determined under the ideal 
setting. Therefore, some pairs could turn out to be more efficient than others for different 
configurations of treatment effect and sample size allocation. When the treatment effects 
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in all regions are significant (statistically or clinically), but not numerically consistent, it 
will be easier to show consistency using special case 2 ( 0)π . However, the consistency 
of special case 2 is more easily affected by sample size. Therefore, using special case 2 
may give us little chance to demonstrate consistency when there are small samples from 
this region. When the treatment effects are homogenous, we have more chance to 
demonstrate the consistency if the special case 1 is considered as the regional 
requirement. In addition to the two special cases, we recommend considering the general 
case in between, e.g. (0.3, 0.3) for three regions and (0.3, 0.375) for four regions. Even 
though the general case may not always perform better than the two special cases, it 
maintains a reasonable probability of demonstrating consistency when it is difficult to use 
one of the two special cases demonstrated in Table 2.10. In addition, the assurance 
probability curve can be used to evaluate the performance of different consistency 
requirements; we prefer the consistency requirement that will lead to higher assurance 
probability when the treatment is effective in the region as well as lower PFCRA when 
there is no treatment effect in the region.  
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CHAPTER THREE  
OPTIMAL DESIGNS FOR MULTI-REGIONAL CLINICAL TRIALS WITH 
REGIONAL CONSISTENCY REQUIREMENT 
 
3.1 Introduction 
With the increasing of globalization of drug development, conducting multi-
regional clinical trials (MRCT) has become the preferred approach for having a new drug 
developed by the pharmaceutical industry. Conducting MRCT could potentially provide 
an opportunity to have the study drug submitted and approved in several regions 
simultaneously. It should at least provide a pathway for a regulatory agency to ensure the 
drug’s safety and efficacy based not only on the overall patient population but also the 
regions of interest. In other words, the primary objective of MRCT is to investigate the 
drug’s overall efficacy across regions while also assessing the drug’s performance in 
individual regions. In order to claim the study drug’s efficacy in specific region(s), the 
local regulatory authority may require the sponsor to provide evidence of consistency in 
the treatment effect between the overall patient population and the local region. Although 
the overall efficacy results could appear to be significant, it is difficult to claim the drug’s 
efficacy for a region of interest if the observed treatment effect shown in this region is 
null or even negative. If the sample size of the region of interest is small, it will be 
challenging to distinguish whether the result is simply due to chance or the true treatment 
effect is indeed much smaller than that observed from the overall results. Therefore, to 
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help assess the regional effect with unambiguous findings, enrolling a sufficient number 
of patients from each region of interest is certainly desirable. 
Different criteria for accessing consistent treatment effect across regions have 
been proposed in the past few years, and sample size determination for the region of 
interest has also been discussed. On the basis of Method 2, Kawai et al. (2008) proposed 
an approach to partition the total sample size to the individual regions to ensure a high 
probability of observing a consistent trend if the treatment effect is positive and uniform 
across regions. Uesaka et al. (2009) introduced four criteria for assessing the consistency 
between the region of interest and the entire patient population and they further discussed 
three rules of sample size allocation. On the basis of Method 1, Quan et al. (2010) 
discussed the sample size requirement for normal, binary and survival endpoint. Ko et al. 
(2010) focused on a specific region and established four criteria for consistency between 
the region of interest and the overall results. Tsou et al. (2012) also proposed a 
consistency criterion to examine whether the overall results can be applied to all 
participating regions; sample size requirements were also discussed.  
It should be noted that most of the developed designs for MRCT only consider 
applying the consistency requirement for a specific region, and the sample size 
proportion to this region is determined, but not to others. In practice, it is uncommon that 
we are only interested in one region of the entire MRCT study. If we are also interested in 
some other regions, there may not be enough samples left to guarantee certain probability 
of success for other regions of interest with the original sample size. In this chapter, we 
propose two optimal designs for MRCT: 1. minimal total sample size design (MTSS); 2. 
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maximal utility design (MU), in which consistency requirements are imposed to all 
regions of interest. The first optimal design will help determine the minimal total sample 
size and the corresponding sample size allocation which can ensure certain overall power 
and assurance probability for all regions of interest. With the fixed total sample size, the 
second optimal design will help determine the optimal sample size allocation which 
maximizes the global utility of the regions of interest. In addition, we also introduce five 
factors which should be taken into consideration when designing MRCT and analyze how 
each factor affects the sample size planning of MRCT.  
We organize this chapter as follows: In section 3.2, we introduce the two optimal 
designs. In section 3.3, we introduce five factors which should be taken into 
consideration when designing MRCT. Sections 3.4 and 3.5 will demonstrate how each 
factor affects the sample size planning of MRCT. In section 3.6, we use hypothetical 
examples to illustrate how to design the MRCT by using the proposed optimal designs 
while taking all the factors into consideration. Finally, we provide a detailed conclusion 
and discussion of our methods in section 3.7. 
 
3.2 Optimal Sample Size Allocation Designs for MRCT 
The assurance probability of one region will increase when more samples are 
allocated to this region. In order to achieve a desired assurance probability for a region of 
interest, we could successively increase the allocation of samples to this region until the 
assurance probability achieves the desired level. Nevertheless, there may not be enough 
samples left for other regions of interest to guarantee their desired assurance probabilities 
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with fixed total sample size. Thus, in order to achieve the desired assurance probabilities 
for all regions of interest, the total sample size increase is sometimes inevitable. However, 
different sample size allocations will lead to different total sample size increases. The 
optimal designs for MRCT should appropriately allocate the total samples to each region 
so that we can ensure certain overall power and assurance probability for all regions of 
interest with minimal total sample size requirement. 
In this section, we propose two optimal designs for MRCT: 1. minimal total 
sample size design; 2. maximal utility design.  
3.2.1 Minimal Total Sample Size Design 
For the conventional clinical trial, the sample size is usually determined to 
achieve certain power (1 )  at the significance level of   with the assumed effect size. 
The consistency requirement imposed for the regions of interest makes the MRCT 
different from the conventional clinical trial in terms of sample size planning. We need to 
determine not only the total sample size for the entire study, but also the sample size 
allocation of each region. In this section, we propose the first optimal design, which 
allows us to find the minimal sample size and the corresponding sample size proportion 
for each region to achieve both the desired overall power and desired assurance 
probabilities of all regions of interest, i.e. 
1, ,Minimize: (with the corresponding , )i i sN f    
Subject to: 
1- ,Power   
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1 , 1, , ,i iAP i j    
where 1   is the desired overall power; 1 i  is the desired assurance probability for 
region i ; j s is the number of regions of interest.  
There is no constraint on total sample size for the minimal total sample size 
design. However, in practice, the determination of total sample size may highly depend 
on the budget for the study. Even though we can find the minimal total sample size with 
the corresponding sample size proportion for each region to achieve all the design 
requirements, the minimal total sample size may also be too large, making it unfeasible 
for sponsors to implement. Thus, the optimal design with fixed sample size is introduced 
below.  
3.2.2 Maximal Utility Design 
With fixed total sample size, we may be unable to satisfy all the desired design 
requirements as mentioned for the minimal total sample size design for some cases. Thus, 
the definition of global utility U  is introduced to evaluate the performance of different 
sample size allocation strategies with the fixed total sample size. We define the global 
utility as follows: 
 
1
j
i i
i
U M AP

   
where iM  is the utility weight for region i which could be related to the number of 
patients or commercial viability of this region, and 
1
1
j
i
i
M

 ; j  is the number of regions 
of interest.  
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The maximal utility design is to find the optimal sample size allocation, which 
maximizes the global utility of the regions of interest on the premise of guaranteeing the 
desired overall power with the fixed total sample size, i.e. 
1
1, ,sMaximize: (with the corresponding , )
j
i i i
i
iU M AP f

  
Subject to: 
1- ,Power   
0 ,N N  
where 1   is the desired overall power; 0N  is the fixed total sample size. 
Under the fixed total sample size, the overall power is not the best choice of 
evaluating the performance of different sample size allocations for the MRCT; we also 
would like to improve the possibility of regional approval based on the consistency 
requirements of each region. The sample size allocation that maximizes the overall power 
may greatly reduce the ability to obtain regional approval for some regions of interest. 
However, the maximal utility design we propose here is to maximize the global benefits 
of the drug by considering regional approval. If the utility weight is proportional to the 
number of patients in each region, the utility U  is the expected number of patients who 
can receive the benefits from this drug. 
 
3.3 Factors to Consider When Designing MRCT 
Most of the proposed methods for MRCT assumed that the treatment effects are 
uniform across regions, however, this assumption may not hold in practice. Some 
47 
 
 
 
historical trials may indicate that the treatment effects may not be exactly uniform across 
regions; the drug may show a higher efficacy in some regions, but lower efficacy in the 
others. For example, the meta-analysis conducted for schizophrenia in Chen et al. (2010) 
has found that the observed treatment effect in the US was generally smaller than that in 
non-US regions. Thus, the first factor to consider is the treatment effect for each region.  
The second factor is the desired assurance probability for each region in the 
minimal total sample size design; the third factor is the utility weight for each region in 
the maximal utility design. Both factors could be different due to patient’s benefit, 
commercial viability, etc. If the disease prevalence is different for each region, in order to 
have more patients get benefits from the drug, the sponsor may consider enrolling more 
patients in the region with high prevalence to ensure a higher assurance probability than 
the other regions. When the maximal utility design is used to find the optimal sample size 
allocation, the utility weight of each region could be determined based on the disease 
prevalence; therefore, more samples will be allocated to the region with high prevalence 
in order to maximize the global utility. In terms of commercial viability, the difference in 
disease prevalence could also lead to a difference in commercial viability after the drug 
approval in each region. If the disease prevalence is positively related to the patients’ 
enrollment rate, the difference in disease prevalence may also affect the time to recruit 
enough patients for each region. Therefore, recruiting more patients from a region with 
high disease prevalence can also speed up the global patients’ enrollment, which highly 
enhances the merit and advantages of conducting an MRCT.  
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The fourth factor to consider is the consistency requirement for each region. In 
practice, the consistency requirements are mainly determined by local regulatory 
agencies, but are still negotiable in some cases. Thus, the consistency requirements are 
very likely different across regions. As mentioned in Luo et al. (2010), the disease 
prevalence and operational capabilities may impact patients’ accrual and their time to 
complete the study. Sometimes, it may be impractical to accrue the same number of 
patients from each region during the same time period due to these extrinsic factors. As a 
result, loosening criteria for the regions by requiring a smaller sample size may be 
considered by the local regulator. Thus, different regions may have different regional 
requirements. Some regions may have certain regional requirements; some regions may 
not have any regional requirements as long as the global result is significant. Some 
regions may require a stringent consistency requirement for regional approval; some 
regions may accept a loose requirement due to some regulatory consideration. Some 
regions may require the sponsor to conduct an MRCT-extension trial, and the final 
decision of the regional approval is based on the samples from both the MRCT and the 
MRCT-extension trial. In terms of the consistency requirement of each region, it is 
always a good idea to interact with local regulators regarding potential regional 
requirements before conducting the MRCT.  
The last factor to consider is which regions are subject to our interest within the 
MRCT. In most cases, we only enroll the patients from the regions in which we are 
interested. Nevertheless, we may want to enroll some patients from some regions of non-
interest due to some practical issues or regulatory considerations. For example, we may 
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want to enroll some patients from the regions of non-interest if we are unable to enroll 
enough patients to guarantee certain overall power. Or we may consider enrolling some 
patients from the regions of non-interest to speed up the entire process of the MRCT if 
the enrollment process is quite slow in the regions of interest. As we mentioned before, 
some regions may require an MRCT-extension trial in addition to the MRCT, and the 
final decision of regional approval is based on the samples from both the MRCT and the 
MRCT-extension trial. In such a case, it is not necessary to ensure a certain level of 
assurance probability for this region within the MRCT even though this region is our 
region of interest. However, we can save some samples for the MRCT-extension trial if 
we enroll as many patients as we can for this region in the MRCT after ensuring desired 
overall power and assurance probability of the other regions of interest.  
In the following two sections, we evaluate how each factor affects the sample size 
planning of the MRCT for the minimal total sample size design and maximal utility 
design, respectively.  
 
3.4 Minimal Total Sample Size Design for MRCT 
3.4.1 Equal Sample Size Allocation Design 
If all the regions included in an MRCT are our regions of interest and we believe 
that the true treatment effects are uniform across the regions, the design with equal 
sample size allocation is the optimal design which can achieve the desired overall power 
and the same level of desired assurance probability with minimal total sample size 
requirement. If the disease prevalence is similar for each region and the patients can be 
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recruited at the same pace, the equal sample size allocation design could also reduce the 
time to finish the entire study.  
To illustrate this idea, we consider an MRCT including three regions. One of the 
recommended combinations of ( , )iπ α  in Chapter 2 for three regions: (0.575, 0.5) is 
considered as the consistency requirement for each region. As discussed in Chapter 2, the 
specific values of and iπ α  are determined to achieve approximately 80% assurance 
probability for each region with the original total sample size of 80% overall power. We 
certainly need to increase the total sample size if a higher assurance probability is desired. 
Denote N  the total sample size calculated by the traditional method to achieve 80% 
power at a one-sided significance level of 0.025, 
*N the sample size needed to achieve 
certain level of assurance probability for all regions, 
* /N Nρ  the necessary fold of 
original sample size. Table 3.1 demonstrates the sample size needed to achieve different 
levels of assurance probability under the equal sample size allocation. For example, we 
need increase the total sample size to 1.49-fold the original sample size in order to 
achieve 85% assurance probability for each region. 
Table 3.1 Sample size increase to achieve certain assurance probability with equal sample size allocation 
, ( , ) (0.575,0.5), , 1,2,3i i i iROI iμ μ π α    
idAP   ρ   iAP   Power 
0.80 1.00 0.82 0.800 
0.85 1.49 0.85 0.928 
0.90 2.50 0.90 0.993 
51 
 
 
 
3.4.2 Minimal Total Sample Size Design when Postulated Treatment Effects are Different 
We only consider an MRCT by not assuming large heterogeneity across regions, 
e.g. 0.5iμ μ . Otherwise, the region with smaller efficacy may need huge samples to 
achieve the same level of assurance probability compared to other regions. When the 
treatment effects are different across regions, the overall treatment effect will be affected 
by the sample size allocation. Although fewer samples are needed to achieve the same 
assurance probability for the region with larger treatment effect, the overall efficacy will 
be reduced when this is considered, which further leads to a larger total sample size 
requirement. Thus, an optimal design should balance both the overall power and the 
assurance probabilities of all regions of interest for an MRCT with different treatment 
effects across regions.  
Denote N   the sample size needed to achieve (1 )β  power at a one-sided 
significance level of α  when the samples are equally allocated to each region, N   the 
total sample size needed to achieve at least (1 )β  overall power and the desired 
assurance probabilities for all regions of interest. Thus 
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We can also interpret N   as the needed sample size to achieve (1 )β  power at a one-
sided significance level of α  under the uniform treatment effect μ   when not considering 
the consistency requirement for regional approval.  
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Let 21 / ( / )N Nρ ρ μ μ     , which is sample size increase compared to the 
traditional clinical trial with treatment effect μ   when considering the consistency  
requirement for regional approval. From this formula, we can see that there are two 
potential reasons why we may need to increase the total sample size to achieve the 
desired overall power and desired assurance probabilities when the treatment effects are 
different in an MRCT. The first is that we impose the consistency requirement for all 
regions of interest; more samples may be needed to satisfy the consistency requirement. 
The second is that more samples may be allocated to the regions with smaller treatment 
effect to minimize the total sample size, which reduces the overall efficacy, and then 
more samples will be needed to achieve (1 )β  power. 
We use two scenarios of different treatment effects: 1 2 3( , , ) (0.8,1,1.2)μ μ μ μ  
and 1 2 3( , , ) (0.5,1,1.5)μ μ μ μ  to illustrate how the different treatment effects affect the 
sample size planning for MRCT, where μ   is the overall efficacy defined before. We 
further assume that we anticipate 80% assurance probabilities for all regions and the 
same regional requirement as section 3.4.1 is imposed to each region, i.e.
( , ) (0.575,0.5)i iπ α  . Table 3.2 shows the minimal amount of sample size increase and 
the corresponding optimal sample size allocation which can achieve at least 80% overall 
power and 80% assurance probability for each region when the treatment effects are not 
homogenous. 
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Table 3.2 Minimal total sample size design when the postulated treatment effects are different 
( , ) (0.575,0.5), 0.8, , 1,2,3i i i idAP ROI iπ α     
1 2 3( , , )μ μ μ   1f  1AP  2f  2AP  3f  3AP  Power   1ρ   
(0.8,1,1.2)μ  0.5 0.8 0.25 0.801 0.25 0.88 0.8 1.11 
(0.5,1,1.5)μ  0.75 0.8 0.12 0.83 0.13 0.96 0.8 2.1 
 
As illustrated in Table 3.2, in order to minimize the total sample size, more 
samples are allocated to the region with smaller treatment effect; we advise allocating as 
many samples as possible to the region with larger treatment effect after achieving the 
desired assurance probabilities for other regions of interest. Take scenario 1 as an 
example: the optimal sample size allocation is 0.50, 0.25 and 0.25 for regions 1-3, 
respectively, which ensures at least 80% overall power and 80% assurance probability for 
each region with the minimal total sample size increase, i.e. 1 1.11ρ   versus the sample 
size calculated by the traditional method with the treatment effect μ  . If we compare 
scenario 1 with scenario 2, we can see that more unbalanced designs are expected to 
minimize the total sample size when there is a large heterogeneity in treatment effect 
among regions. As demonstrated in scenario 2, the minimal sample size is 2.1-fold the 
original sample size even though we allocate 75% to the region with the smallest 
treatment effect.  
54 
 
 
 
3.4.3 Minimal Total Sample Size Design when Desired Assurance Probabilities are 
Different 
Following the previous examples, we assume that the treatment effects are 
uniform across regions and all the three regions included in the MRCT are our regions of 
interest; the combination ( , ) (0.575,0.5)i iπ α   is considered as the consistency 
requirement for all regions. In order to illustrate how the different desired assurance 
probabilities affect the sample size planning for MRCT, we consider two configurations 
of desired assurance probabilities: 1 2 3( , , ) (0.75,0.80,0.85)dAP dAP dAP   and 
1 2 3( , , ) (0.70,0.80,0.90)dAP dAP dAP  . Table 3.3 demonstrates the minimal total sample 
size increase and corresponding sample size proportion of each region to achieve at least 
80% overall power and desired assurance probabilities for all the three regions.  
 
Table 3.3 Minimal total sample size design when the desired assurance probabilities are different 
, ( , ) (0.575,0.5), , 1,2,3i i i iROI iμ μ π α    
1 2 3( , , )dAP dAP dAP  1f  1AP  2f  2AP  3f  3AP  Power   ρ   
(0.75, 0.80, 0.85) 
0.21 0.75 0.30 0.80 0.49 0.89 0.8 1 
0.21 0.75 0.40 0.85 0.39 0.85 0.8 1 
0.31 0.81 0.30 0.80 0.39 0.85 0.8 1 
(0.70, 0.80, 0.90) 
0.14 0.70 0.30 0.80 0.56 0.92 0.8 1 
0.14 0.70 0.35 0.83 0.51 0.90 0.8 1 
0.19 0.74 0.30 0.80 0.51 0.90 0.8 1 
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As illustrated in Table 3.3, in order to minimize the total sample size, more 
samples are allocated to the region with higher desired assurance probability. Without 
total sample size increase, there are still a number of sample size allocations available to 
achieve 80% overall power and the desired assurance probabilities of all regions. We 
only list some of the available sample size allocations in Table 3.3; nevertheless, the 
range of the sample size proportion for each region can be easily found from this table. 
Take scenario 1 as an example: the sample size proportion of region 1 should be between 
21% and 31%, the available sample size proportion of region 2 is between 30% and 40% 
if we fix the sample size proportion of region 1 as 21%. If we fix the sample size 
proportion of region 1 as 31%, there is only one sample size allocation available for 
regions 2 and 3 to achieve 80% overall power and the desired assurance probability for 
all three regions without total sample size increase. The maximal utility design could be 
used to select the optimal sample size allocation among all the available allocations, 
which will be introduced later.  
3.4.4 Minimal Total Sample Size Design when the Regional Requirements are Different 
In order to illustrate how the different regional requirements affect the sample size 
planning for the MRCT, we consider two scenarios of different consistency requirements: 
1. the special case 1 of the proposed unified consistency requirement is imposed on each 
region but with the different value of π , e.g. 1 1( , ) (0,0.5)π α  , 2 2( , ) (0.5,0.5)π α  , 
3 3( , ) (0.6,0.5)π α  ; 2. the special case 2 of the proposed unified consistency requirement 
is imposed on each region but with the different value of iα , e.g. 1 1( , ) (0,0.5)π α  , 
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2 2( , ) (0,0.15)π α  , 3 3( , ) (0,0.10)π α  . Assume that at most 15% of the original total 
sample size can be recruited from region 1 due to some extrinsic and intrinsic factors, so 
we only need to show the positive trend of treatment effect for region 1 after negotiating 
with the local regulatory agency. We further assume that the treatment effects are 
uniform across regions and all the three regions included in the MRCT are our regions of 
interest; we anticipate 85% assurance probability for all regions. Table 3.4 demonstrates 
the minimal total sample size increase and the corresponding sample size proportion of 
each region to achieve at least 80% overall power and 85% assurance probability for each 
region with different regional requirements. 
 
Table 3.4 Minimal total sample size design when the regional requirements are different 
, 0.85, , 1,2,3i i idAP ROI iμ μ    
( , )i iπ α   1f  1AP  2f  2AP  3f  3AP  Power   ρ   
1 1
2 2
3 3
( , ) (0,0.5)
( , ) (0.5,0.5)
( , ) (0.6,0.5)
π α
π α
π α



 
0.11 0.86 0.32 0.85 0.57 0.92 0.8 1 
0.11 0.86 0.47 0.92 0.42 0.85 0.8 1 
0.15 0.90 0.32 0.85 0.53 0.90 0.8 1 
0.15 0.90 0.43 0.90 0.42 0.85 0.8 1 
1 1
2 2
3 3
( , ) (0,0.5)
( , ) (0,0.15)
( , ) (0,0.10)
π α
π α
π α



 0.11 0.85 0.40 0.85 0.49 0.85 0.8 1 
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As illustrated in Table 3.4, there are multiple sample size allocations available to 
achieve 80% overall power and 85% assurance probability for each region without a 
sample size increase for scenario 1. The minimal sample size proportion for region 1 is 
11%; furthermore, the available sample size proportion of region 2 is between 32% and 
47% if we fix the sample size proportion of region 1 as 11%. Since we assume that the 
maximum sample size of region 2 is 15% of the original sample size, the available 
sample size proportion of region 2 is between 32% and 43% if we fix the sample size 
proportion of region 1 as 15%. For scenario 2, there is only one sample size allocation 
available to achieve 80% overall power and 85% assurance probability for each region 
without sample size increase: 1 2 3( , , ) (0.11,0.40,0.49)f f f  . Thus, it is always possible to 
find one or multiple sample size allocations to achieve both desired overall power and 
desired assurance probability for each region with minimal sample size increase even 
though each region has different consistency requirements for regional approval.  
3.4.5 Minimal Total Sample Size Design when We Are Interested in Some of the Regions 
in an MRCT 
Following the previous examples, we assume that the treatment effects are 
uniform across regions; the combination ( , ) (0.575,0.5)i iπ α   is considered as the 
consistency requirement for regions of interest 1 and 2; we anticipate 80% assurance 
probability for these two regions; the maximum sample size we can recruit from regions 
1 and 2 are 35% and 50% of the original sample size respectively. We would like to 
determine the minimal sample size for regions 1 and 2 to ensure their desired assurance 
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probability and the minimal sample size should be enrolled from region 3. Table 3.5 
demonstrates the available sample size allocations which achieve at least 80% overall 
power and 80% assurance probability for regions 1 and 2 with the minimal sample size 
increase.  
 
Table 3.5 Minimal total sample size design when we are interested in some of the regions in an MRCT 
, 1,2,3, 0.80, ( , ) (0.575,0.5), , 1,2j i i i ij dAP ROI iμ μ π α      
1f  1AP  2f  2AP  3f  3AP  Power   ρ   
0.30 0.80 0.30 0.80 0.40 0.85 0.8 1 
0.30 0.80 0.50 0.90 0.20 0.75 0.8 1 
0.35 0.83 0.30 0.80 0.35 0.83 0.8 1 
0.35 0.83 0.50 0.90 0.15 0.71 0.8 1 
 
As illustrated in Table 3.5, in order to achieve at least 80% assurance probability 
for the regions of interest 1 and 2, we need to enroll at least 30% of the total sample size 
from the two regions, respectively. Therefore, we can enroll at most 40% from region 3. 
If we would like to enroll as many patients as we can from the regions of interest to 
guarantee higher assurance probability, then 35% and 50% of the total sample size are the 
maximal sample size we can get for these two regions and we only need to enroll 15% 
from region 3 to guarantee 80% overall power. Nevertheless, if we are also interested in 
region 3, but the MRCT-extension trial is required for regional approval, then we may 
only enroll the necessary amount of samples for regions 1 and 2 to ensure their desired 
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assurance probabilities and enroll as many patients as possible in the MRCT for region 3. 
In this case, we may prefer the sample size allocations: 30%, 30%, and 40% for regions 1, 
2 and 3, respectively. In addition, one point we want to emphasize is that enrolling 
patients from the regions of non-interest can help with increasing the overall power, but it 
is little help to increase the assurance probability for the regions of interest. If the desired 
assurance probability of the region of interest cannot be achieved by the maximal 
available sample size, it is better to lower the desired assurance probability or try to enroll 
more patients from the region of interest.  
 
3.5 Maximal Utility Design for MRCT 
The maximal utility design is different from the minimal total sample size design, 
which does not focus on the specific regions of interest individually, but considers the 
MRCT as a whole. The global utility of the regions of interest could be interpreted as the 
global patients’ benefits, global commercial viability, etc., depending on how the utility 
weights are selected for each region. When multiple sample size allocations are available 
to achieve the desired overall power and desired assurance probabilities for all regions of 
interest, the global utility could be used to evaluate the performance of the different 
sample size allocations, which is the first application of maximal utility design. The 
second application of maximal utility design is to find a sample size allocation that 
maximizes pre-defined global utility while guaranteeing overall power at a desired level 
should a limited total sample size make it unable to achieve the desired assurance 
probability for each region simultaneously.  
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In consideration of the factors we mentioned before, section 3.5.1 will 
demonstrate how to select the optimal sample size allocation among all the available ones; 
section 3.5.2 will demonstrate how to select the optimal sample size allocation when not 
all the desired assurance probabilities of the regions of interest are achievable 
simultaneously with limited total sample size.  
3.5.1 Maximal Utility Design: the First Application 
Following the examples in section 3.4, we assume that three regions are included 
in an MRCT and we anticipate 80% assurance probability for all regions of interest. 
Table 3.6 lists the settings of the factors for different scenarios.  
 
Table 3.6 Settings of different scenarios for maximal utility design 
Scenario 
1 2 3( , , )μ μ μ  1 2 3( , , )M Μ Μ  ( , )i iπ α  ROI   0ρ  
1 (1,1,1)μ  (1/3,1/3,1/3) (0.575,0.5) 
1 2 3( , , )R R R  1 
2 (0.8,1,1.2)μ  (1/3,1/3,1/3) (0.575,0.5) 
1 2 3( , , )R R R  1.3 
3 (1,1,1)μ  (0.25,0.35,0.40) (0.575,0.5) 
1 2 3( , , )R R R  1 
4 (1,1,1)μ  (1/3,1/3,1/3) 
1 1
2 2
3 3
( , ) (0.50,0.5)
( , ) (0.55,0.5)
( , ) (0.60,0.5)
π α
π α
π α



 
1 2 3( , , )R R R  1 
5 (1,1,1)μ  (1/2,1/2,0) (0.575,0.5) 
1 2( , )R R  1 
 
Scenario 1 is under the ideal settings: the treatment effects, utility weights and 
consistency requirements are all the same for each region. We follow one of the examples 
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of different treatment effects across regions in section 3.4.2 for scenario 2, but assuming 
that the maximal sample size is 1.3-fold the original sample size since it is unable to 
achieve the desired assurance probability for all regions without sample size increase. In 
scenario 3, we select different utility weights for different regions. In scenario 4, we 
assume that different regional requirements are imposed on different regions. Scenario 5 
follows one of the examples in section 3.4.5. We set both of the utility weights as 0.5 for 
regions 1 and 2, but 0 for region 3 because region 3 is not our region of interest for this 
case.  
 
Table 3.7 Optimal sample size allocations of the maximal utility design for different scenarios  
Scenario 1f  1AP  2f  2AP  3f  3AP  Power  U 
1 1/3 0.822 1/3 0.822 1/3 0.822 0.8 0.822 
2 0.62 0.89 0.22 0.81 0.16 0.84 0.83 0.844 
3 0.30 0.80 0.30 0.80 0.40 0.85 0.8 0.825 
4 0.33 0.86 0.34 0.84 0.33 0.81 0.8 0.834 
5 0.35 0.83 0.50 0.90 0.15 0.71 0.8 0.865 
 
Table 3.7 demonstrates the optimal sample size allocation for each scenario, 
and maximizes the global utility of the regions of interest among all the allocations which 
can achieve at least 80% overall power and 80% assurance probabilities for the regions of 
interest. Take Scenario 2 as an example: Table 3.8 lists some of the available sample size 
allocations which can achieve at least 80% overall power and 80% assurance 
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probabilities for all regions of interest. As illustrated in Table 3.8, the sample size 
proportion for region 1 should be between 46% and 68%. Among all the available sample 
size allocations, the allocation of 1 2 3( , , ) (0.62,0.22,0.16)f f f  is the optimal sample size 
allocation which maximizes the global utility of the three regions of interest under these 
settings.  
 
Table 3.8 Selected available sample size allocations for scenario 2 in Table 3.6  
1 2 3 0
1
( , , ) (0.8,1,,1.2) , ( , ) (0.575,0.5), , 1.3, , 1, 2,3
3
i i i iM ROI iμ μ μ μ π α ρ      
1f  1AP  2f  2AP  3f  3AP  Power  0ρ  U 
0.46 0.80 0.41 0.90 0.13 0.80 0.85 1.3 0.835 
0.47 0.80 0.35 0.87 0.18 0.85 0.85 1.3 0.839 
0.47 0.81 0.40 0.90 0.13 0.80 0.84 1.3 0.836 
0.68 0.92 0.20 0.80 0.12 0.80 0.81 1.3 0.842 
 
As illustrated in Table 3.7, the optimal sample size allocation is to assign the same 
number of samples to each region under the ideal setting, i.e., scenario 1, as there is no 
reason to consider more samples in one region than in others. We allocate more samples 
to the region with smaller treatment effect in order to maximize the global utility when 
the treatment effects are different across regions, i.e., scenario 2. When the utility weights 
are different for each region, i.e., scenario 3, we allocate as many samples as we can to 
the region with the highest utility weight to maximize the global utility. It is hard to tell 
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how to allocate the samples to maximize the global utility when each region has different 
regional requirements, i.e., scenario 4. The optimal sample size allocations highly depend 
on the consistency requirements of each region, whereas the numerical method can 
always be applied to find the optimal sample size allocation. When we are only interested 
in some of the regions, i.e., scenario 5, in order to maximize the global utility of the 
regions of interest, we enroll as many samples as we can from the regions of interest.  
3.5.2 Maximal Utility Design: the Second Application 
We use the same examples as section 3.5.1 to illustrate the second application of 
maximal utility design but assuming that the desired assurance probabilities are 85% for 
all regions  of interest and the maximal sample size is 1.3-fold the original sample size of 
80% overall power, i.e., 0 1.3  .  
Table 3.9 demonstrates the optimal sample size allocations of the minimal total 
sample size design without total sample size limitation and the maximal utility design 
with at most 30% sample size increase. The first and second rows of each scenario 
correspond to the minimal total sample size design (MTSS) and maximal utility design 
(MU), respectively. The value of 0ρ  for MTSS design is the minimal total sample size 
needed to ensure at least 80% overall power and 85% assurance probability for all 
regions of interest; the value of 0ρ  for MU design is the maximal total sample size, 
which is fixed as 1.3 in our case. Take scenario 2 as an example, the minimal total sample 
size increase is 50% with the specific sample size allocation 
1 2 3( , , ) (0.55,0.28,0.17)f f f   in order to achieve at least 80% overall power and 85% 
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assurance probabilities for all regions of interest. Thus, it is clear that we are unable to 
achieve all the design requirements with only 30% sample size increase. If we adopt the 
maximal utility design, the global utility of the regions of interest is maximized with the 
sample size allocation 1 2 3( , , ) (0.62,0.22,0.16)f f f  . 
 
Table 3.9 Comparison of minimal total sample size design without total sample size limitation and maximal 
utility design with limited total sample size 
Scenario Design 0ρ  1f  1AP  2f  2AP  3f  3AP  Power  U 
1 MTSS 1.49 1/3 0.85 1/3 0.85 1/3 0.85 0.93 0.85 
 MU 1.3 1/3 0.84 1/3 0.84 1/3 0.84 0.89 0.84 
2 MTSS 1.50 0.55 0.85 0.28 0.85 0.17 0.86 0.89 0.85 
 MU 1.3 0.62 0.89 0.22 0.81 0.16 0.84 0.83 0.84 
3 MTSS 1.49 1/3 0.85 1/3 0.85 1/3 0.85 0.93 0.85 
 MU 1.3 0.19 0.75 0.37 0.86 0.44 0.89 0.89 0.84 
4 MTSS 1.49 0.28 0.85 0.36 0.85 0.36 0.85 0.93 0.85 
 MU 1.3 0.32 0.87 0.34 0.83 0.34 0.83 0.89 0.84 
5 MTSS          
 MU 1.3 0.26 0.80 0.38 0.86 0.36 0.85 0.89 0.83 
 
As illustrated in Table 3.9, in order to maximize the global utility, the optimal 
sample size allocation is to assign the same number of samples to each region under the 
ideal settings, i.e., scenario 1. In general, more samples will need to be distributed to the 
region with larger utility weight and smaller treatment effect to be able to maximize the 
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global utility. Note that we determine the specific number of the sample size proportion 
of each region by the numerical method. For scenario 5, it is impossible to achieve 85% 
assurance probabilities for region 1 with limited sample sizes, i.e., up to 35% of original 
sample size, even if we enroll more and more samples from region 3. Nevertheless, the 
maximal utility design could also be applied to find the optimal sample size allocation 
which maximizes the global utility. The global utility of the regions of interest is always 
maximized when we enroll as many samples as we can from the regions of interest. The 
new sample size proportions of regions 1 and 2 with 30% total sample size increase are 
0.26 (=0.35/1.3) and 0.38 (=0.50/1.3), respectively. The remaining 36% samples are 
enrolled from region 3, which only helps increase the overall power.  
 
3.6 Hypothetical Examples 
In sections 3.4 and 3.5, we evaluate how each factor affects the sample size 
planning for the minimal total sample size design and maximal utility design, 
respectively, by assuming that other factors are the same across regions. In practice, it is 
very common to meet the situation where more than one factor is different for all regions. 
Thus, the optimal designs should take all the factors into consideration when designing 
MRCT.  
In this section, we provide three examples to illustrate the practical applications of 
the proposed optimal designs. Assume that we conduct a randomized, double-blinded, 
active-control MRCT in patients from 4 regions: Japan (JP), the European Union (EU), 
the United States (US) and China (CN). The original total sample size is calculated based 
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on the assumptions of overall treatment effect: 5μ   and standard derivation: 21.86σ  . 
In order to achieve 80% overall power with one-sided significance level 0.025α  , the 
total sample size needed is 300pts/arm. The sponsor can only afford 30% ( 1.3)ρ   
sample size increase besides 300pts/arm due to the budget limitations; therefore, the 
maximal total sample size for this MRCT is 390pts/arm. Table 3.10 lists the settings of 
each factor for different regions under two different desired assurance probability 
configurations.  
 
Table 3.10 Settings of each factor for different regions  
Scenario 1 : ( , , , ) (0.80,0.85,0.78,0)JP EU US CNdAP dAP dAP dAP   
Scenario 2 : ( , , , ) (0.85,0.85,0.85,0)JP EU US CNdAP dAP dAP dAP   
Region 
iμ  ( , )i iπ α   (Min,Max)  ROI   
Japan (JP) 5 (0, 0.5) (5%, 15%) YES 
European Union (EU) 6 (0.6, 0.5) (20%, ) YES 
United States (US) 4 (0.5, 0.5) (20%, ) YES 
China (CN) 5 (0, 0.5) (5%, ) NO 
 
As illustrated in Table 3.10, we assume that the true treatment effects are 5, 6, 4 
and 5 for Japan, the European Union, the United States and China, respectively. These 
assumptions are made based on historical trials and early stage data from each region. 
Due to the disease prevalence and regulatory considerations, there are some sample size 
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limitations and consistency requirements imposed on each region after negotiating with 
the local regulators. For example, each region needs to enroll at least 5% of the original 
total sample size, 15pts/arm; the maximal sample size we can enroll from Japan is 15%, 
i.e., 45pts/arm due to the disease prevalence and population limitation; The United States 
and the European Union require to enroll at least 20% of the original total sample size, i.e. 
60pts/arm, from their regions due to safety considerations. China requires the sponsor to 
conduct an MRCT-extension trial in addition to the MRCT, and at least 5% of the 
original total sample size, i.e.15pts/arm, have to be enrolled from China within the 
MRCT. In terms of consistency requirements, we only need to show the positive trend for 
Japan population due to the small sample size enrollment from this region; however, the 
observed treatment effects for the United States and the European Union need to preserve 
at least 50% and 60% of the overall treatment effect, respectively; even though China is 
not our region of interest within the MRCT, we also would like to see how many chances 
there are to observe a positive result for China. We consider different desired assurance 
probability configurations to illustrate how to use both minimal total sample size design 
and maximal utility design together to find the optimal sample size allocations. The 
results are demonstrated in Tables 3.11-3.12.  
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Table 3.11 Minimal total sample size design for scenario 1 and scenario 2 
Scenario 1 : ( , , , ) (0.80,0.85,0.78,0)JP EU US CNdAP dAP dAP dAP   
JPf  JPAP  EUf  EUAP  USf  USAP  CNf  CNAP  Power  ρ   
0.08 0.816 0.45 0.941 0.40 0.780 0.07 0.799 0.8 0.98 
0.09 0.830 0.45 0.941 0.40 0.780 0.06 0.781 0.8 0.98 
0.10 0.844 0.45 0.941 0.40 0.780 0.05 0.760 0.8 0.98 
0.08 0.816 0.46 0.944 0.41 0.785 0.05 0.760 0.8 0.98 
Scenario 2 : ( , , , ) (0.85,0.85,0.85,0)JP EU US CNdAP dAP dAP dAP   
JPf  JPAP  EUf  EUAP  USf  USAP  CNf  CNAP  Power  ρ   
0.10 0.853 0.34 0.913 0.51 0.851 0.05 0.769 0.8 1.072 
 
As illustrated in Table 3.11, there are four sample size allocations available for 
scenario 1 which can achieve at least 80% overall power and the desired assurance 
probability of all regions of interest with the minimal total sample size, i.e., 98% of the 
original total sample size. When more than one factor is different across regions, the total 
sample size could be reduced with the optimal sample size allocation(s). We save 2% of 
total sample size, i.e. 6pts/arm in this case with the sample size allocations listed in Table 
3.11. In scenario 1, we can enroll at most 7% of patients from China and the chance to 
observe a positive result is about 80%. We still have a 76% chance to observe a positive 
result if we only enroll 5% of patients from China. For scenario 2, we anticipate 85% 
assurance probability for each region of interest; the minimal total sample size increase is 
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7.2% and the corresponding sample size allocation is ( , , , )JP EU US CNf f f f 
(0.10,0.34,0.51,0.05) .  
If the sponsor would like to conduct the MRCT with the original sample size and 
a different utility weight is selected for each region based on disease prevalence, then the 
maximal utility design could be used to find the optimal sample size allocation. Since 
China is not our region of interest within the MRCT, the utility weight of China is set as 
0. Table 3.12 demonstrates the optimal sample size allocation which maximizes the 
global utility of the regions of interest under different utility weight configurations. For 
example, when the configuration of the utility weight is
( , , , ) (0.20,0.40,0.40,0)JP EU US CNM M M M  , we enroll 15% from Japan, which is the 
maximal sample size available, 40% from the United States and the European Union, 
respectively, and the remaining 5% from China. When the configuration of the utility 
weight is ( , , , ) (0.10,0.45,0.45,0)JP EU US CNM M M M  , we enroll 7% from Japan, which is 
the minimal sample size needed to guarantee 80% assurance probability, 44% from the 
United States and the European Union, respectively, and the remaining 5% from China. 
Table 3.12 Maximal utility design for scenario 1with original sample size: 300pts/arm 
( , , , ) (0.80,0.85,0.78,0)JP EU US CNdAP dAP dAP dAP  , N=300pts/arm, Power=0.8 
Utility Weights JPf  JPAP  EUf  EUAP  USf  USAP  CNf  CNAP  U 
(0.20,0.40,0.40,0) 0.15 0.897 0.40 0.926 0.40 0.785 0.05 0.762 0.864 
(0.14,0.43,0.43,0) 0.11 0.858 0.42 0.933 0.42 0.794 0.05 0.762 0.863 
(0.10,0.45,0.45,0) 0.07 0.801 0.44 0.941 0.44 0.803 0.05 0.762 0.865 
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3.7 Conclusion and Discussion 
The first objective of MRCT is similar to the conventional clinical trial, which is 
to show the efficacy of the drug in the overall patient population. Nevertheless, the 
second objective of MRCT is to test the consistency of the drug’s performance in all 
regions or some regions of interest, which makes the MRCT different from the 
conventional clinical trials. In addition to the overall efficacy, consistency requirements 
may need to be satisfied in order to approve the drug in a local region. The unified 
consistency requirement we proposed in Chapter 2 provides a general method to assess 
the consistency of treatment effects between the region of interest and the entire study 
population. In this chapter, we proposed two optimal designs in consideration of the 
consistency requirements of all regions of interest; they provide some solutions to the 
sample size planning of MRCT. 
A number of factors should be considered when designing MRCT; we introduce 
five of them which we think are important and highly affect the success of the MRCT in 
the regions of interest and the sample size planning:  
1. Treatment effect for each region 
2. Desired assurance probability for each region  
3. Utility weight for each region 
4. Consistency requirement for each region 
5. Regions of interest  
The treatment effect of each region could be estimated from the historical trials 
and the early stage data of each region. We recommend conducting the MRCT only when 
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the treatment effects are not heterogeneous, e.g. 0.5i  . The desired assurance 
probability and utility weight of each region could be determined by sponsor in 
consideration of disease prevalence, commercial viability, etc. If the utility weight of 
each region is chosen based on the disease prevalence of the regions of interest, the 
global utility can be interpreted as the global patients’ benefit. The consistency 
requirement is mainly determined by a local regulatory agency, but sometimes still 
negotiable; therefore, it is very likely to be different from region to region. We highly 
recommend that the sponsor interact with each local regulator regarding the potential 
consistency requirement along with the overall efficacy for regional approval before the 
planning stage of MRCT. Besides these five factors, we also need to consider if there are 
sample size limitations for each region, e.g. the minimal sample size requirement, the 
maximal sample size available, etc. which also play an important role in the sample size 
planning of MRCT.  
The objective of the minimal total sample size design is to find the optimal 
sample size allocation which can ensure certain overall power and assurance probability 
for all regions of interest with minimal total sample size requirement. No matter how 
different the factors are, most of the time we can find the optimal sample size allocation 
which requires the minimal total sample size through numerical methods. Nevertheless, 
the “minimal” total sample size could still be too large for the sponsor to implement in 
practice. In this case, we can lower the desired assurance probabilities of some regions of 
interest so that the desired assurance probabilities are achievable with the maximal 
sample size. Or we can adopt the maximal utility design to find the optimal sample size 
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allocation which maximizes the global utility of the regions of interest when the total 
sample size is fixed. The maximal utility design can also be used to make a choice when 
multiple sample size allocations are available to achieve the desired overall power and 
desired assurance probabilities of the regions of interest.  
To summarize, the two proposed optimal sample size allocation designs provide 
solutions to the sample size planning of MRCT; they make the MRCT more efficient for 
regional approval and enhance the benefits of MRCT in terms of cost reduction and time 
saving in drug development. 
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CHAPTER 4  
ADAPTIVE DESIGN FOR MULTI-REGIONAL CLINICAL TRIALS WITH 
REGIONAL CONSISTENCY REQUIREMENT 
 
4.1 Introduction 
In clinical investigation of the treatment effect, adaptive designs have been widely 
used in designing clinical trials. An adaptation in clinical trials is referred to as a change 
or modification made to a clinical trial before and during the conduct of the study (Chow, 
2011). Adaptive design methods are usually developed based on observed treatment 
effect to make changes in sample size, study dose, study endpoint, or other features of the 
design. Chow et al. (2005) define an adaptive design of a clinical trial as a design that 
allows adaptations or modifications to some aspects of the trial after its initiation without 
undermining the validity and integrity of the trial. Sample size re-estimation is one of the 
most commonly used adaptive designs, which calculates the needed sample size for the 
next stage based on the observed values.  
For a common disease, conducting a trial with a fixed design may be sufficient, 
but utilizing the available regional information (e.g., regional treatment effect and 
standard deviation) from historical data at the design stage can also be a key to success. 
The optimal sample size designs we proposed in Chapter 3 can handle this situation.  
However, if no historical information is available for a disease, an adaptive design may 
be preferable by applying different re-allocation ratios to different regions and possibly 
by increasing sample size after an interim analysis of the ongoing trial. Nevertheless, the 
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adaptive design for multi-regional clinical trials is much more complex than that of the 
traditional clinical trial. During the interim analysis, we not only need to re-calculate the 
total sample size to guarantee the overall power, but also need to determine the new 
sample size allocation of the next stage to ensure a certain level of assurance probability 
for each region of interest based on the observed data. For the traditional adaptive design, 
the interim decision is only determined by one observed effect size; nevertheless, we 
need to incorporate the effect size of each region in an MRCT to make decisions for both 
the entire MRCT study and each individual region. In general, there are three options for 
the traditional adaptive design at interim: stop the clinical trial for efficacy if the observed 
effect size is in the favorable zone; continue to the next stage if the observed effect size is 
in the promising zone; stop the clinical trial for futility if the observed effect size is in the 
unfavorable zone. In terms of the adaptive design for MRCT, the three options are 
applicable to both the entire MRCT study and each individual region. Thus, we not only 
need to determine whether to stop the entire MRCT or continue to the next stage, but we 
also need to make the decision for each individual region of whether we can stop either 
for efficacy or futility or continue to the next stage.  
Even though both the topics of MRCT and adaptive design are not new, there are 
only a very limited amount of adaptive designs proposed for MRCT. Luo et al. (2010) 
proposed an optimal adaptive design for MRCT in which an optional supplemental stage 
of the MRCT may be needed to provide additional data to address local regulation 
requirements. Chen et al. (2012) proposed an adaptive strategy to identify an imbalanced 
factor or effect modifier based on the blinded data and also provided a stratified analysis 
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method to adjust for the imbalanced factor. In this chapter, we propose an unblinded 
region-level adaptive design to perform sample size re-calculation and re-allocation at 
interim based on the observed values of each region. The entire MRCT and each 
individual region are allowed to be stopped at interim for efficacy or futility, or to 
continue to the next stage with sample size re-allocation and re-calculation which are 
performed to ensure certain conditional power and conditional assurance probability of 
each region of interest. If it is impossible to achieve both the desired conditional power 
and conditional assurance probability of each region with the maximal total sample size, 
the conditional global utility of the regions of interest could be used to determine the 
sample size allocation for next stage.  
We organize this chapter as follows: In section 4.2, we introduce the statistical 
framework for the adaptive design, including the test statistic of each stage, conditional 
power, conditional assurance probability and conditional success rate. In section 4.3, a 
detailed step-by-step demonstration of the adaptive design will be introduced, including 
the initial sample size planning, adaptation strategies at interim and the final decision 
rules for the entire MRCT and each individual region. The comparisons between the 
adaptive design and the classical design in terms of overall power, success rate of each 
region and average sample size will be demonstrated in section 4.4. In this section, we 
also demonstrate that the overall type I error rate will be controlled when appropriately 
selecting the stopping boundaries. In section 4.5, we provide a detailed conclusion and 
discussion of our methods. 
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4.2 Statistical Framework 
4.2.1 Classical Multi-Regional Clinical Trials  
Suppose that we have a placebo-controlled trial with the primary endpoint of each 
region following a normal distribution with true treatment effect i   and the same known 
variance 
2 . Assume that iD  is the observed treatment effect for region i and in  is the 
number of patients in each arm of region i, then  
22
,~  i i
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D N
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If the overall treatment effect is the weighted average of the regional treatment effect and 
we consider the sample size proportion as the weight, i.e.
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The hypothesis for testing this overall treatment effect is given as 
0 : 0 versus : 0aH H    
The power of rejecting this hypothesis at the one-sided significance level of    is as 
follows:  
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where   denotes the cumulative probability function of the standard normal distribution.  
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If the special case 1 of the proposed unified consistency requirement, i.e. i iD D is 
considered as the consistency requirement for regional approval, then the assurance 
probability of region i is defined as 
 
1( | )i i iAP P D D Z z      
The detailed mathematical derivations of the assurance probability are given in Chapter 2. 
Note that the rate of retention of the overall treatment effect i  could be different for 
each region.  
At the end of the MRCT, if the overall treatment effect is significant at the 
predetermined   level, then we can claim the global efficacy of the drug. After that, the 
regional treatment effect will be evaluated based on the consistency requirement of each 
region: i iD Dπ . The regional efficacy will be claimed if the consistency requirement is 
satisfied, otherwise, no treatment effect is claimed for this region. If the overall results do 
not show the drug’s efficacy, then the entire MRCT fails and it is not necessary to 
evaluate if the consistency requirement is satisfied.  
4.2.2 Adaptive Multi-Regional Clinical Trials  
For simplicity, we consider that there is only one interim look in the MRCT and 
the methodology could be extended to multiple looks. Denote 1N  and 2N  the initial 
planned sample size for stage 1 and stage 2, respectively, *
2N  the new sample size for 
stage 2 after sample size re-calculation and re-allocation, 
ijf  the initial planned sample 
size proportion of region i at the jth stage, *
2if  the new sample size proportion of region i 
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at the second stage after sample size re-calculation and re-allocation. Denote 
1
ˆ
iD  and 
2
1
ˆ
i  
the observed treatment effect and variance of region i at interim, then the observed 
overall treatment effect at stage 1 
1 1 1
1
ˆ ˆ
s
i i
i
D f D

 . We assume that the treatment effect of 
region i at the second stage 2iD  follows a normal distribution with true treatment effect 
2i  and variance 
2
2i . We further assume that the variances of all regions are the same, 
i.e. 2 2 , 1, , , 1,2ij i s j     since we first focus on the parameter of primary interest, 
i.e. the treatment effect, and ignore the effect of the nuisance parameter, i.e. the variance 
for this moment. Thus 
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4.2.2.1 Test Statistics for the Adaptive Design of MRCT 
A number of adaptive designs are available for now; we select one of the most 
commonly used adaptive designs, i.e. Cui, Hung & Wang method, to illustrate our ideas. 
The test statistics for stage 1 and 2 are demonstrated as follows: 
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Note that we assume 1Z  and 
*
2Z  are independent standard normal variable. Even 
if we change the sample size in *
2Z  based on the observed value of 1Z , 
*
2Z  stays standard 
normal. Thus, the weighted Z test statistic of stage 2, i.e. 2T  also follows standard normal 
distribution.  
4.2.2.2 Conditional Power for the Adaptive Design of MRCT 
The concept of conditional power is widely used in adaptive design to do sample 
size re-estimation based on the observed values. A tremendous sample size will be 
needed to achieve certain (e.g. 80%) conditional power for the next stage if the observed 
treatment effect is too small. Thus, we may consider stopping the clinical trial if the 
conditional power based on the original sample size planning is smaller than a given 
threshold, e.g. 0.35cPower  . Because multiple regions are included in an MRCT, the 
conditional power of the adaptive design for MRCT will involve the observed values of 
each region at interim and the assumptions of each region for the next stage. Note that the 
assumptions of treatment effect and variance of some or all regions for the next stage 
could be changed based on the observed values of each region. If no region is dropped 
80 
 
 
 
based on the conditional success rate, which will be introduced in next section, then the 
conditional power for MRCT is defined as follows:  
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where   is the information time,   is the fold of the original sample size for stage 2. 
If some regions are dropped because of a small conditional success rate, then the 
conditional power can be calculated as follows: 
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where *
2 2 2
1
,
s
i i
i
f 


  s is the number of regions remaining in the MRCT for the next 
stage.  
4.2.2.3 Conditional Assurance Probability and Conditional Success Rate for the Adaptive 
Design of MRCT 
The assurance probability is the probability of satisfying the regional consistency 
requirement(s) given the overall efficacy, which could be interpreted as the success rate 
of regional approval if we observe a positive trial. When the entire MRCT is conducted in 
the adaptive way, then the conditional assurance probability calculated at interim can 
serve the same role of assurance probability; nevertheless, the conditional assurance 
probability will incorporate the observed values of each region at interim and the 
assumptions of each region for the next stage. Denote ( )s s   the number of remaining 
regions for the next stage,   the information time when the interim analysis is conducted, 
i.e. 1 /N N ,  the fold of original sample size for stage 2, then the conditional 
assurance probability of region i is defined as follows: 
2 22 2 1 1 1 2 2
ˆ ˆ( | , , , 1, , , , , 1, , )i i i j j k kcAP P D D T z D j s k s            
The detailed mathematical derivations of 2icAP  are given below. 
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If no samples are enrolled from region i for the next stage, i.e. *
2 0if  , then the 
conditional assurance probability of region i could be calculated using the following 
formula: 
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The conditional assurance probability along with the conditional power could be 
used to determine the sample size planning for the next stage based on observed values of 
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each region. Similar to the assurance probability, the conditional assurance probability is 
highly affected by the sample size proportion of the region as well. We may get a high 
conditional assurance probability as long as we allocate a large proportion of samples to 
this region even when the conditional power is very low. Thus the conditional assurance 
probability is not a good criterion for the interim analysis to determine whether to stop 
each region for futility or continue to the next stage. We propose a more reasonable 
futility stopping criterion, i.e. conditional success rate, which is defined as follows:  
2 22 2 1 1 1 2 2
ˆ ˆ( , | , , 1, , , , , 1, , )i i i j j k kcSR P D D T z D j s k s      μ απ σ μ σ  
Numerically, the conditional success rate is equal to the product of conditional power and 
conditional assurance probability, i.e. 2 2*i icSR cPower cAP . If the conditional success 
rate is smaller than a given threshold, e.g. 2 0.30icSR   with the original sample size 
planning, i.e. * *
2 2 2 2, , 1,i iN N f f i s   , then we will have little chance to show the 
consistency in the treatment effect between region i and the overall efficacy at the end of 
MRCT. Thus, we may consider dropping this region at interim. By dropping the non-
efficacious regions at interim, on one hand we protect the patients of the non-efficacious 
regions; on the other hand we avoid losing too much overall power because of including 
the non-efficacious regions.  
Similar to the optimal designs we proposed in Chapter 3, both the overall power 
and assurance probabilities of remaining regions of interest should be taken into 
consideration when we conduct the sample size re-calculation and re-allocation at the 
interim of study. The detailed adaptive strategies will be introduced in the next section.   
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4.3 Adaptive Strategies 
Denote 1 and 2  the efficacy stopping boundaries for stage 1 and stage 2, 
respectively. At the interim analysis, if the conditional power based on the original 
sample size planning is less than a given threshold, e.g. 0.35cPower  , we stop the entire 
MRCT at interim. Thus, the entire MRCT will be stopped for efficacy or futility if 
11 1
T z   or 0.35cPower  , respectively. We will continue to the next stage if the 
observed overall treatment effect is in the promising zone, i.e. 
11 1
T z   and 
0.35cPower  . The sample size re-calculation and re-allocation will be performed to 
determine the sample size planning for the next stage by utilizing conditional power and 
conditional assurance probability. For each individual region, we drop the region at 
interim if the conditional success rate is less than a given threshold, e.g. 2 0.30icSR  . The 
flow chart of the adaptive design is illustrated in Figure 4.1. The detailed step-by-step 
demonstration of the proposed region-level adaptive design is introduced below. 
 
 
 
 
 
8
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Figure 4.1 The flow chart of the proposed region-level adaptive design
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The proposed adaptive design involves 3 steps:  
For simplicity, we assume that we are interested in all the regions included in an MRCT. 
Step 1. Initial sample size planning (ISSP) 
In Chapter 3, we propose two optimal sample size allocation designs: minimal total 
sample size design and maximal utility design. The initial sample size planning could be 
determined by utilizing one or the other of them depending on different scenarios. Denote 
maxN  the maximal total sample size. If we can find the total sample size maxN N and the 
corresponding sample size allocation to achieve the desired overall power and assurance 
probability of each region, the minimal total sample size design could be used to 
determine the initial sample size planning. If we could not find the sample size allocation 
which achieves the desired overall power and assurance probability of each region with 
the maximal sample size maxN , the maximal utility design could be used to determine the 
initial sample size planning. The minimal total sample size design and maximal utility 
design are demonstrated as follows: 
a. Minimal total sample size design: find the total sample size and sample size 
allocation for each region to achieve the desired overall power and assurance 
probability of each region of interest, i.e.
max 1, ,Find ( ) and the sample size proportion of each region ,i i sN N f    
Subject to: 
1-Power   
1 , 1, ,i iAP i s     
89 
 
 
where 1   is the desired overall power; 1 i  is the desired assurance probability  
of region i .  
b. Maximal utility design: find the optimal sample size allocation, which maximizes the 
global utility on the premise of guaranteeing the desired overall power with the fixed 
total sample size, i.e.
1
1, ,sMaximize: (with the corresponding , )
s
i i i
i
iU M AP f

  
Subject to: 
1- ,Power   
0 ,N N  
where 1   is the desired overall power; 0N  is the fixed total sample size. 
Step 2. Decision making and sample size adaptation at interim 
Scenario 1: If the test statistic 1T  is rejected at the 1  significance level and all regions 
satisfy the consistency requirement for regional approval, i.e.
1 1
ˆ ˆ
i iD D , then we stop the 
entire MRCT by claiming regional efficacy for all regions. 
Scenario 2: If the test statistic 1T  is rejected at the 1  significance level and some regions 
e.g. 1, ,k j  satisfy the consistency requirement, then we stop these regions for 
efficacy. For the other regions i.e. 1, ,k j s   in which the consistency requirement is 
not satisfied, for each region we may either decide to stop at stage 1 without pursuing a 
claim in this region or enroll more patients to ensure that this region satisfies the 
consistency requirement with certain probability if we believe the outcome 
1 1
ˆ ˆ
i iD D  
from stage 1 may not reflect the true treatment effect in region i due to limited sample 
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size from this region. We can make the decision based on the simple assurance 
probability, which is defined as follows: 
22 1 1 1 2 2
ˆ ˆ ˆ( | , , 1, , , , )
ii i i j j i i
sAP P D D D j s        
Denote 1iN  and 2iN  the sample size of region i at stage 1 and stage 2, respectively. The 
simple assurance probability could be calculated as follows: 
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The needed sample size 2iN  at stage 2 to ensure 21 i  simple assurance probability can 
be calculated as follows:  
2
2
2
1 2 1
1 2
2 2
2
2
2
2 2 2 2 2 2
2 1 2 2 1 1 1 1 2 1
1
2 1
2
1
1
ˆ ˆ
2
ˆ ˆ ˆ ˆ ˆ ˆ( ) 2(( )( ) ) ( ) 0
i
i
i
i i i
i i i
i i
i
i
i i i i i i i i i i i i i
isAP
N N
N N
N
D D
Z
D D D D N Z N D D
N
N N



 

      
 

 
 
        
 
91 
 
 
2 22
2 22 2
2 2 1 1 1 1 221 1 1
2 2 2
2 1 2 1 2 1
ˆ ˆ ˆˆ ˆ 2( )( )
ˆ ˆ ˆ( ) ( )
(
( )
) i ii i i i i i i iii i i
i
i i i i i i
Z D D D N ZD D
D
N Z
N
D D
 
    
     
  
   
  
      
If the simple assurance probability of region i is smaller than a given threshold with the 
original planned sample size for this region, e.g. 2 0.35isAP  , we may consider stopping 
this region at stage 1. If we believe that the true treatment effect is consistent with the 
overall efficacy, i.e.
2 1
ˆ
i iD   even though the observed treatment effect at stage 1 does 
not show the consistency, the proposed formula for 2iN  could be used to calculate the 
sample size needed for stage 2 to achieve certain simple assurance probability. However, 
if the total sample size needed at stage 2 is greater than the maximal remaining total 
sample size, i.e.
2 2 max 1
s
j
k j
N N N N

   , the global utility of the remaining regions could 
be used to find the optimal sample size allocation for the next stage, i.e., 
*
2 2 2 2 , ,Maximize: (with the corresponding , )
s
k k k
k j
k j ssU M sAP f

   
Subject to: 
2 max 1N N N   
where 2kM  is the new utility weight for region k at stage 2. It should be pointed out that 
enrolling more patients at stage 2 is little help to increase 2isAP  when 11 1T z  ,
1 1
ˆ ˆ
i iD D  and small alpha is spent at stage 1, e.g. O’Brien-Fleming (OBF). One example 
will be provided in the conclusion and discussion section. 
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Scenario 3: If the entire MRCT shows little efficacy at interim e.g. 0.35cPower  , then 
we stop the entire MRCT for futility. It is not necessary to test the consistency 
requirements for each region in this case.  
Scenario 4: If the overall result is in the promising zone i.e.
11 1
T z   and 0.35cPower  , 
first we evaluate if it is necessary to continue to the next stage for each region based on 
conditional success rate. Similar to the simple assurance probability, if the conditional 
success rate with the original planned sample size is smaller than a given threshold, e.g.
0.30icSR  , then this region will be dropped at stage 1, and the sample size planning for 
stage 2 will not involve this region anymore.  
If we can find the total sample size *
2 max 1N N N   and the corresponding sample 
size proportions for the remaining regions to achieve the desired conditional power and 
desired conditional assurance probabilities, the minimal total sample size design could be 
used to determine the sample size planning for stage 2, i.e.  
* *
2 max 1 2Minimize: ( ) (with the corresponding , 1, )iN N N f i s      
Subject to: 
21-cPower   
21 , 1, ,i icAP i s      
where 21   is the desired conditional power; 21 i  is the desired conditional assurance 
probability for region i ; s s  is the number of remaining regions at stage 2.  
If we cannot find the sample size allocation which achieves the desired 
conditional power and desired conditional assurance probability for the remaining regions 
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with the maximal remaining sample size *
2 max 1N N N  , the sample size proportion of 
each region for stage 2 could be determined to maximize the conditional global utility of 
the remaining regions on the premise of guaranteeing certain conditional power, i.e.,  
*
2 2 2 2
1
Maximize: (with the corresponding , 1, , )
s
i i i
i
cU M cAP f i s


     
Subject to: 
21-cPower    
*
2 max 1N N N   
where 2iM  is the new utility weight for region i at stage 2. 
Step 3: Final decision 
At the end of MRCT, we can claim the regional efficacy for region i as long as the 
overall result is significant, i.e. 
1 , 1,2iiT z iα    and the consistency in treatment effect 
between region i and the overall efficacy is also proven, i.e. ˆ ˆ , 1, ,i iD D i j  . 
Otherwise, we are unable to claim the regional efficacy. 
The proposed region-level adaptive design provides another chance to modify the 
design based on the observed values of each region at interim. If the observed treatment 
effects of some regions or all regions show very high efficacy, we can claim regional 
efficacy for these regions at interim. Nevertheless we stop some regions or the entire 
MRCT for futility if the observed treatment effects show little efficacy. No matter which 
scenario we end up with, we save some patients for the entire MRCT study. If the 
treatment effects are in the promising zone, the sample size re-estimation and re-
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allocation based on the conditional power and conditional assurance probability will 
enhance the chance of success at the end of MRCT for the remaining regions. In other 
words, the proposed adaptive design for MRCT can utilize the remaining samples at stage 
2 more efficiently compared with the classical design. 
Similar to the optimal sample size allocation designs proposed in Chapter 3, if 
there are multiple sample size allocations available to achieve the desired conditional 
power and conditional assurance probabilities, the global utility could also be used to 
select the optimal sample size allocation among these allocations. The next section will 
demonstrate that the proposed adaptive design has better performance than the classical 
design in terms of the overall power and success rate of each region; the overall type I 
error rate will be controlled when the stopping boundaries are selected appropriately.  
 
4.4 Comparisons between Proposed Adaptive Design and Classical Design for 
MRCT 
For simplicity, we assume that two regions (e.g. the European Union and the 
United State) are included in an MRCT and both regions are subject to our interest. In 
order to compare the proposed adaptive design and the classical design, we consider two 
scenarios: uniform treatment effect and different treatment effects across regions. Within 
each scenario, we use three examples to demonstrate how the adaptive design performs 
compared to the classical design when the trial is underpowered, overpowered and 
powered as planned, respectively.  
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4.4.1 Initial Sample Size Planning  
Assume that the standard derivation 21.86σ   for both scenarios; the 
significance level of the test for the entire MRCT is 0.025. Each region needs to preserve 
70% of the overall treatment effect to claim regional efficacy, i.e. 0.7 , 1,2iD D i  . The 
objective of the initial sample size planning is to ensure 80% overall power and 80% 
assurance probability for each region. Table 4.1 demonstrates the initial sample size 
planning by using the optimal designs we proposed in Chapter 3. The overall power, 
assurance probabilities and success rates are listed for different power conditions.  
 
Table 4.1 Initial sample size planning and the overall power, assurance probabilities and success rates when the 
trial is underpowered or overpowered 
Scenario 1:  1 2, (5,5)A A    
  1 2,T T    N   1f  1AP  1SR  2f  2AP  2SR  Power  
ISSP (5, 5) 300 0.5 0.822 0.657 0.5 0.822 0.657 0.800 
Underpowered (4, 4) 300 0.5 0.801 0.489 0.5 0.801 0.489 0.611 
Overpowered (6.5, 6.5) 300 0.5 0.861 0.821 0.5 0.861 0.821 0.954 
Scenario 2:  1 2, (4,6)A A    
ISSP (4, 6) 358 0.71 0.808 0.646 0.29 0.874 0.700 0.800 
Underpowered (3.2, 4.8) 358 0.71 0.806 0.492 0.29 0.838 0.512 0.611 
Overpowered (5.2, 7.8) 358 0.71 0.830 0.791 0.29 0.922 0.879 0.954 
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For scenario 1, the sample size planning is based on the assumption of uniform 
treatment effect across regions, i.e.  1 2, (5,5)A A μ μ . Under equal sample size allocation, 
the minimal sample size to ensure all the design requirements is 300pts / armN  , which 
is the same as the original sample size when not considering consistency requirements. If 
the true treatment effects are identical to the assumed ones, the overall power, assurance 
probability and success rate of each region are 0.8, 0.822 and 0.657, respectively. If the 
trial is underpowered as the second example of scenario 1, the overall power is only 
0.611 and the success rate of each region is reduced to 0.489 from 0.657 due to low 
overall power; nevertheless, the assurance probability is still over 0.8. For scenario 2, the 
sample size planning is based on the assumption that the treatment effects are different, 
i.e.  1 2, (4,6)A Aμ μ  . The minimal total sample size to ensure all the design requirements 
is 358 pts / armN  , which is a 19.33% increase compared to scenario 1. The 
corresponding sample size proportion of regions 1 and 2 are 71% and 29% respectively. 
If the true treatment effects are identical to the assumed ones, i.e.  1 2, (4,6)T Tμ μ  , the 
overall power is 0.8; the assurance probability and success rate for region 1 are 0.808 and 
0.646; the assurance probability and success rate for region 2 are 0.874 and 0.700. If the 
trial is overpowered as the third example of scenario 2, i.e.  1 2, (5.2,7.8)T Tμ μ  , the 
overall power is 0.954; the assurance probability and success rate for region 1 are 0.83 
and 0.791; the assurance probability and success rate for region 2 are 0.922 and 0.879. 
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4.4.2 Power and Success Rate Performance Simulation: Design  
Ten thousand simulations will be run to compare the adaptive design with the 
classical design for MRCT in terms of overall power, success rate of each region, and 
average sample size. Assume that the interim look happens after enrolling 50% patients 
from each region, i.e. 0.5θ  . For example, the interim analysis will be conducted when 
75 pts/arm are enrolled from each region for scenario 1 and when 127 pts/arm and 52 
pts/arm are enrolled from region 1 and 2 respectively for scenario 2. The O’Brien-
Fleming boundaries are selected as the efficacy boundaries, i.e. 1 0.00153, α
2 0.0245 α ; the corresponding Z test statistics boundaries are 11 2.9626Z   and
21
1.9686Z   respectively. We can claim the overall efficacy for the entire MRCT at 
interim if 1 2.9626,T  or at the end of the MRCT if 2 1.9686T  . Due to the reason 
mentioned before, we will stop region i without claiming regional efficacy if 1 2.9626T   
but 
1 1
ˆ
i iD D . During the interim analysis, if the conditional power is less than 0.35, i.e.
0.35cPower  , we stop the entire MRCT for futility; for each region, if the conditional 
success rate is less than 0.30, i.e. 0.30icSR  , we stop the region for futility. The maximal 
sample size is set as 1.5-fold the original planned sample size, i.e. 1max 450 pts / armN 
and 2max 537 pts / armN  for scenarios 1 and 2. If we cannot find the sample size 
allocation to achieve all the design requirements with the maximal sample size, the 
conditional global utility can be used to determine the sample size allocation for stage 2. 
We assign the same utility weight to each region, i.e. 2 0.5, 1,2iM i  . If only one region 
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is left for stage 2 based on the conditional success rate, then the sample size for this 
region is calculated to achieve the 80% overall power. All the settings are summarized in 
Table 4.2.  
 
Table 4.2 Settings for the adaptive design 
Stopping Boundaries Adaptation 
1 1
2 2
2
( ) 0.0015(2.9626)
( ) 0.0245(1.9686)
futility stopping boundary for 
the entire MRCT: 0.35
futility stopping boundaryfor
each region: 0.30i
T
T
cPower
cSR
α
α
 
 


 
2
12 22
1
max
2
max
_ 0.8
_ 0.8
0.5
450 pts/arm
537 pts/arm
i
d cPower
d cAP
M M
N
N


 


 
 
4.4.3 Power and Success Rate Performance Simulation: Results  
Tables 4.3 and 4.4 show the simulated overall power and success rate of each 
region for the proposed adaptive design and compare them with the classical design for 
scenarios 1 and 2, respectively. Since the simulated average sample size using adaptive 
design might be different from the original planned sample size of the classical design, in 
order to make a fair comparison, we also compare the results of the adaptive design with 
the classical design when enrolling the same sample size as the simulated average sample 
size using adaptive design.  
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Table 4.3 Comparisons between adaptive design and classical design for scenario 1 
Condition Design Power 
1SR  2SR  aveN  
Powered as planned 
1 2
1 2
( , ) (5,5)
( , ) (5,5)
T T
A A
μ μ
μ μ


 
Adaptive design 0.838 0.734 0.739 298 
Classical design 0.800 0.657 0.657 300 
 0.797 0.655 0.655 298 
Underpowered 
1 2
1 2
( , ) (4,4)
( , ) (5,5)
T T
A A
μ μ
μ μ


 
Adaptive design 0.692 0.607 0.603 335 
Classical design 0.611 0.489 0.489 300 
 0.659 0.530 0.530 335 
Overpowered  
1 2
1 2
( , ) (6.5,6.5)
( , ) (5,5)
T T
A A
μ μ
μ μ


 
Adaptive design 0.960 0.853 0.853 251 
Classical design 0.9537 0.821 0.821 300 
 0.915 0.774 0.774 251 
 
As illustrated in Tables 4.3-4.4, the proposed adaptive design can always beat the 
classical design in terms of overall power and success rate of each region no matter 
whether the trial is underpowered, overpowered or powered as planned. For example, 
when the MRCT is conducted using the proposed adaptive design, if the assumed 
treatment effects are uniform as in scenario 1, we can gain a 4.1% increase in power and 
8% increase in success rate when the trial is powered as planned; if the assumed 
treatment effects are different as in scenario 2, the power is increased from 91.21% to 
94.73% when the trial is overpowered; the success rates are increased from 74.65% to 
82.89% and from 81.84% to 88.47% for region 1 and 2, respectively. 
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Table 4.4 Comparisons between adaptive design and classical design for scenario 2 
Condition Design Power 
1SR  2SR  aveN  
Powered as planned 
1 2
1 2
( , ) (4,6)
( , ) (4,6)
T T
A A
μ μ
μ μ


 
Adaptive design 0.839 0.707 0.772 345 
Classical design 0.800 0.646 0.700 358 
 0.786 0.6342 0.685 345 
Underpowered 
1 2
1 2
( , ) (3.2,4.8)
( , ) (4,6)
T T
A A
μ μ
μ μ


 
Adaptive design 0.696 0.576 0.631 384 
Classical design 0.611 0.492 0.512 358 
 0.642 0.517 0.541 384 
Overpowered  
1 2
1 2
( , ) (5.2,7.8)
( , ) (4,6)
T T
A A
μ μ
μ μ


 
Adaptive design 0.9473 0.8289 0.8847 296 
Classical design 0.9538 0.7913 0.8296 358 
 0.9121 0.7465 0.8184 296 
 
Thus, the proposed adaptive design can benefit MRCT from both the overall 
power and the success rate of each region. The next section will illustrate that the overall 
type I error rate will be controlled when appropriately selecting the stopping boundaries 
and maximal sample size.  
4.4.4 Overall Type I Error Rate Control Simulation: Design and Results 
One hundred thousand simulations will be run to test whether the overall type I 
error rate is controlled at 0.025 for different stopping boundaries. The maximal total 
sample size can also affect the overall type I error rate; for simplicity, we fix it as 1.5-fold 
the original planned sample size as before. We continue using the O’Brien-Fleming 
boundaries for efficacy stopping boundaries; six configurations of conditional power and 
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conditional success rate futility boundaries are considered to test whether the overall type 
I error rate is controlled at 0.025 for scenarios 1 and 2, respectively.  
 
Table 4.5 Overall type I error rate for different futility stopping boundaries 
Scenario 
2( , )icPower cSR  Overall Type I error rate 
1 
1 2
1 2
( , ) (0,0)
( , ) (5,5)
T T
A A
μ μ
μ μ


 
(0.05, 0) 0.0255 
(0.15, 0.10) 0.0253 
(0.25, 0.20) 0.0243 
(0.35, 0.30) 0.0238 
(0.45, 0.40) 0.0225 
(0.50, 0.45) 0.0222 
2 
1 2
1 2
( , ) (0,0)
( , ) (4,6)
T T
A A
μ μ
μ μ


 
(0.05,0) 0.0255 
(0.15, 0.10) 0.0253 
(0.25, 0.20) 0.0245 
(0.35, 0.30) 0.0241 
(0.45, 0.40) 0.0229 
(0.50, 0.45) 0.0222 
  
As illustrated in Table 4.5, the overall type I error rate is controlled at 0.0238 and 
0.0241 for scenarios 1 and 2 if the futility boundaries 2( , ) (0.35, 0.30)icPower cSR  as 
section 4.4.2-4.4.3 for the overall power and success rate simulation. The overall type I 
error rate will be inflated for both scenarios if the futility boundaries 2( , )icPower cSR are 
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as low as (0.15, 0.10) and (0.05, 0); Based on the simulation results, the overall type I 
error rate will be controlled at 0.025 as long as the futility stopping boundaries 
2( , )icPower cSR are greater than (0.25, 0.20). Thus, the overall type I error rate could be 
well controlled by selecting the futility boundaries appropriately. However, the overall 
power and success rate will be reduced if the futility boundaries are high e.g. 
2( , ) (0.50, 0.45)icPower cSR  ; therefore, the benefits of adaptive design compared to 
classical design may be reduced under this situation. 
 
4.5 Conclusion and Discussion 
In this chapter, we propose a region-level adaptive design that provides more 
flexibility when designing multi-regional clinical trials. In most cases, the MRCT is 
designed under the assumption of uniform treatment effect across regions due to lack of 
evidence of heterogeneity. However, the assumption is rarely verified before conducting 
the MRCT and it is uncommon to expect the uniform treatment effect across regions 
because of various intrinsic and extrinsic factors. The overall power and assurance 
probability of each region will be affected as long as the assumptions of one region are 
not correct. Thus the classical design for MRCT may not be the best choice if we are not 
confident of the treatment effect in each individual region. The proposed unblinded 
region-level adaptive design provides another chance to correct the original assumption 
of treatment effect in each region based on the observed data and make the sample size of 
the next stage more efficient through sample size re-estimation and re-allocation by 
utilizing the methods we proposed. Even though we do not change the original 
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assumption of treatment effect in each region at interim when the sponsor is confident in 
that, the proposed unblinded adaptive design can also highly enhance the overall power 
and success rate of each region no matter whether the trial is underpowered, overpowered 
or powered as planned, as illustrated in Tables 4.3-4.4. The overall power and success 
rate of each region should be further improved when we modify the original assumption 
of each region at interim if necessary by integrating the observed information and 
original assumptions, which will be our future work.   
We considered the OBF boundaries as our efficacy stopping boundaries and 
conditional power and conditional success rate of each region as our futility stopping 
criteria for the entire MRCT and each region, respectively. As illustrated in section 4.4, 
the overall type I error rate is controlled when the conditional power and conditional 
success rate futility stopping boundaries are greater than 0.25 and 0.20, respectively. 
Thus the overall type I error rate can be controlled at 0.025 with appropriate stopping 
boundaries and maximal sample size. Besides the OBF boundaries, other efficacy 
stopping boundaries, e.g. Pocock, Haybittle-Peto and Wang-Tsiatis, can also be 
considered and the simulation method could be used to find the conditional power and 
conditional success rate futility boundaries which control the overall type I error rate. 
As we mentioned before, enrolling more patients at stage 2 is little help to 
increase 2isAP  when 11 1T z  , 1 1
ˆ ˆ
i iD D  and small alpha is spent at stage 1. We use two 
examples to illustrate this point. Assume that two regions are included in an MRCT with 
the same treatment effect and standard deviation, e.g. 5 =21.86, 1,2i i iμ σ ， , so 
300pts/arm will be needed to ensure 80% overall power at significance level of 0.025. 
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The Pocock and O’Brien-Fleming boundaries (OBF) employ the different alpha spending 
functions; the probability of early rejection is high for Pocock boundaries, on the 
contrary, it is very low for OBF boundaries. The stopping boundaries at information time 
0.5 are listed in Table 4.6 for Pocock and OBF, respectively. 
 
Table 4.6 Stopping boundaries at information time 0.5 for Pocock and O’Brien-Fleming 
 
1α   11Z α   2α   21Z α   
Pocock 0.0155 2.157 0.0138 2.201 
OBF 0.0015 2.9626 0.0245 1.9686 
 
Take OBF boundaries as an example: we can claim the overall efficacy at interim 
when the observed overall treatment effect is greater than 7.48, i.e.
1
ˆ 7.48D  . We use the 
same consistency requirement as before, i.e.
1 1
ˆ ˆ0.7iD D , so the regional efficacy can be 
claimed at interim for region i when 
1
ˆ 5.24iD  . If we cannot claim regional efficacy at 
interim based on the observed values, i.e. 
1
ˆ 5.24iD  , then the chance to satisfy the 
consistency requirement at the end of MRCT is less than 50% based on the original 
assumption of treatment effect, i.e. 2 5i   no matter how many samples will be enrolled 
from this region for the next stage. In such a case, we may consider stopping the entire 
MRCT without pursuing regional efficacy for this region. However, when the Pocock 
boundaries are selected, we can claim the overall efficacy at interim when the observed 
overall treatment effect is greater than or equal to 5.45, i.e.
1
ˆ 5.45D  ; the regional 
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efficacy can be claimed when 
1
ˆ 3.81iD  . So long as the observed overall treatment effect
1
ˆ 7.14( 5 / 0.7)D   , we can increase the chance of satisfying the consistency requirement 
through enrolling more samples from this region at stage 2 based on the original 
assumption of treatment effect, i.e. 2 5i  . For example, assume that the observed 
treatment effects of the entire group and region i are 5.5 and 3.5 respectively. Table 4.7 
lists the sample size needed for region i at stage 2 to achieve different levels of simple 
assurance probability.  
 
Table 4.7 Sample size needed at stage 2 to achieve different levels of simple assurance probability 
_ id sAP  0.6 0.7 0.8 
2iN  86 243 557 
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CHAPTER 5  
SUMMARY AND FURTHER DISCUSSION 
 
Countries around the world desire to provide quality public health care, but there 
are limitations on resources available to generate the evidence needed to establish the 
safety and efficacy of innovative drugs and to meet local regulatory requirements. The 
globalization of drug development through multi-regional clinical trials (MRCT) 
provides a solution to this problem. Moreover, we can highly reduce the total cost for 
sponsor by conducting multi-regional clinical trials instead of multiple regional clinical 
trials; conducting MRCT is also a solution to drug lag compared to bridging studies. But 
while MRCT provides many benefits, it also presents many challenges. In this 
dissertation, we propose some methodologies to provide solutions to some of these 
challenges. 
 
5.1 Summary  
In Chapter 2, we propose a unified consistency requirement in consideration of 
regional approval for multi-regional clinical trials, which generalizes the consistency 
requirements proposed by Ko et al. (2010), Chen et al. (2012) and Tsong et al. (2012). In 
addition, we make recommendations for choosing the value of the parameters defining 
the proposed requirement for the number of regions from 2 to 6 in consideration of 
practical sample size increase. Under the ideal setting (where the treatment effect and 
standard deviation are uniform across regions and samples are evenly allocated to each 
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region), the recommended combinations give each region at least an 80% probability of 
satisfying consistency requirements with the original sample size of 80% power. If we 
increase the sample size to 1.5- or 2-fold the original sample size, each region will have 
approximately 85% and 90% probability of satisfying the regional requirements, 
respectively. In the end, we introduce the assurance probability curve to evaluate 
different consistency requirements. In Chapter 3, we propose two optimal sample size 
allocation designs, i.e., minimal total sample size design and maximal utility design. We 
first introduce the five factors which should be taken into consideration when designing 
MRCT. The first factor is the treatment effect of each region, which could be estimated 
from historical trials or early stage data of each region. The second factor is the assurance 
probability of each region that the sponsor anticipates in consideration of disease 
prevalence, commercial viability, etc. The third factor is the utility weight of each region, 
which could be determined by sponsor when designing MRCT using maximal utility 
design. The fourth factor is the consistency requirement that will be imposed to each 
region, which is mainly determined by local regulatory agencies, but is still sometimes 
negotiable. Thus, the consistency requirement is very likely to be different from region to 
region. The last but not least important factor is which regions are subject to our interest 
in the MRCT. Considering all the factors, the minimal total sample size design aims to 
find the minimal total sample size and the corresponding sample size allocation which 
can guarantee certain overall power and assurance probability for each region of interest. 
When the “minimal” total sample size is still too large for the sponsor to implement, the 
maximal utility design could be used to find the sample size allocation which maximizes 
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the global utility of the regions of interest with the fixed total sample size. The global 
utility can also be considered as a measure to select the optimal sample size allocation 
when multiple sample size allocations are available to achieve the desired overall power 
and desired assurance probabilities. In Chapter 4, we propose a region-level adaptive 
design for multi-regional clinical trials with sample size re-estimation and re-allocation at 
interim based on the observed values of each region. We can determine not only whether 
to stop the entire MRCT based on the conditional power, but also whether to stop each 
region based on the conditional success rate at interim. The proposed region-level 
adaptive design provides another chance to modify the original trial planning based on 
the observed values of each region. The simulation results also demonstrate that the 
adaptive design can beat the classical design no matter whether the trial is underpowered, 
overpowered or powered as planned in terms of the overall power and success rate of 
each region. The overall type I error rate is controlled with appropriate stopping 
boundaries and maximal total sample size.  
To summarize, the proposed methodologies in this dissertation provide solutions 
to some of the challenges for MRCT. Each region can specify its own parameters of 
( , )i i   in the proposed unified consistency requirement in consideration of safety, 
sample size limitation and other specific reasons. The optimal sample size allocation 
designs give a solution to the sample size planning, which can guarantee certain overall 
power and probabilities of satisfying the consistency requirement for all regions of 
interest. The proposed region-level adaptive design makes MRCT more efficient by 
applying sample size re-estimation and re-allocation at interim. 
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5.2 Further Discussion: Binary and Survival Endpoint 
All the methodologies we proposed in Chapters 2-4 focus on the continuous 
endpoint; they can also be extended to binary and survival endpoint.  
5.2.1 Binary Endpoint 
Suppose ~ ( , )l li i in B N p  is the number of events from the lth treatment group in 
region i, and ˆ /l li i ip n N  is the estimate of the event rate , , and 1, , .
l
ip i t c i s  There 
are three major measures of treatment effect for binary endpoint: 
1. risk difference (RD): ˆ ˆt ci i ird p p    
2. relative risk (RR): ˆ ˆ/t ci i irr p p  
3. odds ratio (OR): 
ˆ ˆ(1 )
ˆ ˆ(1 )
t c
i i
i c t
i i
p p
or
p p



  
The overall treatment effect could be estimated either from the pooled data or weighted 
combination of regional treatment effects as the continuous endpoint. However, it is 
difficult to derive the correlation of regional treatment effect and overall treatment effect 
if the pooled data are used to derive the overall treatment effect, at least for the relative 
risk and odds ratio. Thus, we use the weighted combination of regional treatment effects 
to estimate the overall treatment effect for binary endpoint. The distributions of regional 
treatment effect and overall treatment effect for different measures of binary endpoint are 
demonstrated in Table 5.1.  
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Table 5.1 Distributions of regional treatment effect and overall treatment effect for different measures of binary 
endpoint 
Risk difference: 
1
s
j
j
j
n
rd rd
N
   
Regional  
treatment effect 
(1 ) (1 )
~ ( , )
t t c c
t c i i i i
i i i
i
p p p p
rd N p p
n
  
   
Overall  
treatment effect 
2
1 1
( (1 ) (1 ))
~ ( , )
t t c cs s
j j j j j j
j
j j
n n p p p p
rd N rd
N N 
  
   
Relative Risk: 
1
log( ) log( )
s
j
j
j
n
rr rr
N
   
Regional  
treatment effect 
(1 ) / (1 ) /
log( ) ~ (log( / ), )
t t c c
t c i i i i
i i i
i
p p p p
rr N p p
n
  
  
Overall  
treatment effect 
2
1 1
((1 ) / (1 ) / )
log( ) ~ ( log( ), )
t t c cs s
j j j j j j
j
j j
n n p p p p
rr N rr
N N 
  
   
Odds Ratio: 
1
log( ) log( )
s
j
j
j
n
or or
N
   
Regional  
treatment effect 
(1 ) 1 1 1 1 1
log( ) ~ (log( ), ( ))
(1 ) (1 ) (1 )
t c
i i
i c t t t c c
i i i i i i i
p p
or N
p p n p p p p

  
  
  
Overall  
treatment effect 
2
1 1
1 1 1 1
log( ) ~ ( log( ), ( ))
1 1
s s
j j
j t t c c
j j j j j j
n n
or N or
N N p p p p 
  
 
   
 
Table 5.2 lists the available criteria which could be used to assess the consistency 
of treatment effect between the local region and the entire study for different measures of 
111 
 
 
binary endpoint. In order to assess the consistency in risk difference, we can test whether 
the regional risk difference preserves some proportion of overall risk difference, i.e. 
i ird rdπ  . There are two optional consistency criteria for relative risk. The first is to 
test whether the regional risk reduction preserves some proportion of the overall risk 
reduction, i.e. ( 1) ( 1)i irr rrπ    ; the second is to test whether the regional relative 
risk preserves some proportion of overall relative risk on logarithmic scale, i.e. 
log( ) log( )i irr rrπ  , which is equivalent to test whether 
i
irr rr
π . The assessment of 
consistency for odds ratio can adopt the same criteria as relative risk.  
 
Table 5.2 Consistency criteria for different measures of binary endpoint 
 Consistency criteria 
Risk difference 
i ird rdπ   
Relative risk ( 1) ( 1)i irr rrπ     
log( ) log( ) ii i irr rr rr rr
ππ     
Odds ratio ( 1) ( 1)i ior orπ     
log( ) log( ) ii i ior or or or
ππ     
 
Based on the distributions and criteria proposed for different measures of binary 
endpoint, the combination of ( , )i iπ α  in the proposed unified consistency requirement can 
be determined by the same method we employed in Chapter 2 and then the proposed 
optimal and adaptive designs can be applied to designing MRCT for binary endpoint.  
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5.2.2 Survival Endpoint 
For a survival endpoint, the following proportional hazard model is often 
considered: 
 1 0
( ) ( )t t eγλ λ
  
where 1( )tλ  is the hazard function for the treatment group, 0 ( )tλ  is the hazard function 
for the control group; e
γ
 is the hazard ratio between the treatment and control. The 
power calculation is often based on the log-rank test 
~ ( ,1)
2
E
T N
γ
 
where E  is the expected number of events from the two groups combined. Thus  
2 4
ˆ ~ ( , )
ˆ
T
N
EE
γ γ  
where Eˆ  is the expected number of E . Therefore, γˆ  is the estimate of γ , 
ˆ
eγ  is the 
estimate of hazard ratio and (
ˆ
1 eγ ) is the estimate of the hazard reduction for the 
treatment. For a given one-sided significance level α  and power 1 β , the required total 
number of events from the two groups is 
 
2
1 1
2
4( )z z
E
α β
γ
 
   
For the same reason as binary endpoint, we also use the weighted combination of 
regional treatment effects to estimate the overall treatment effect for survival endpoint, i.e.
1 1
ˆ ˆ , where 1
s s
j j j
j j
w w
 
  γ γ , which was also mentioned in Quan et al. (2009). If we 
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consider the number of events /j jw E E  as the weight (similar to using sample size as 
the weight for continuous endpoint), then 
1
4
ˆ ~ ( , )
s
j
j
j
E
N
E E
γ γ . Because hazard reduction 
is often used for measuring the treatment effect for a survival endpoint, the consistency 
assessment could test whether the regional hazard reduction preserves some proportion of 
overall hazard reduction, i.e. (1 ) (1 )i ie e  
γ γπ . Based on the distributions and the 
proposed criterion for survival endpoint, the combination of ( , )i iπ α  in the proposed 
unified consistency requirement can be determined by the same method we employed in 
Chapter 2 and then the proposed optimal and adaptive designs can be applied to 
designing MRCT for survival endpoint. 
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APPENDIX 
R Functions for Calculation of Assurance Probability and Success Rate 
 
APint<-function(low1,low2,up1,up2,a1){ 
  AP=integrate(function(x) { 
    sapply(x, function(x) { 
      integrate(function(y) 1/(2*pi)*exp(-(x^2+y^2)/2), low1+low2*x, 
up1+up2*x,stop.on.error = F)$value 
    }) 
  }, a1, Inf,stop.on.error = F)$value    
  return(AP) 
} 
 
Two Regions: 
SRfun2_r1<-function(amu1,amu2,tmu1,tmu2,f1,alpha,beta,pi1,alpha1,rho){   
  f2=1-f1 
  zalpha=qnorm(1-alpha) 
  zbeta=qnorm(1-beta)   
  zalpha1=qnorm(1-alpha1)   
  amu=f1*amu1+f2*amu2 
  tmu=f1*tmu1+f2*tmu2 
  c1=pi1/(1-pi1*f1)*sqrt(f1*(1-f1))    
  c2=(pi1*tmu-tmu1)/amu/(1-pi1*f1)*sqrt(f1*rho)*(zalpha+zbeta)+zalpha1/(1-
pi1*f1)*sqrt(1-2*pi1*f1+pi1**2*f1)     
  c3=sqrt(f1) 
  c4=sqrt(1-f1) 
  c5=(1-tmu/amu*sqrt(rho))*zalpha-tmu/amu*sqrt(rho)*zbeta   
  a1=(c2*c4+c1*c5)/(c4+c1*c3)   
  low1=c5/c4 
  low2=-c3/c4   
  if (c1==0){ 
    up1=Inf 
    up2=0 
  } 
  else { 
    up1=-c2/c1 
    up2=1/c1 
  }   
  SR=APint(low1,low2,up1,up2,a1) 
  return(SR)  
} 
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R2_AP<-function(amu1,amu2,tmu1,tmu2,f1,alpha,beta,pi1,alpha1,pi2,alpha2,rho){   
  f2=1-f1   
  amu=f1*amu1+f2*amu2 
  tmu=f1*tmu1+f2*tmu2   
  zalpha=qnorm(1-alpha) 
  zbeta=qnorm(1-beta)     
  power=pnorm((tmu/amu*sqrt(rho)-1)*zalpha+tmu/amu*sqrt(rho)*zbeta)   
  SR_r1=SRfun2_r1(amu1,amu2,tmu1,tmu2,f1,alpha,beta,pi1,alpha1,rho) 
  AP_r1=SR_r1/power 
  SR_r2=SRfun2_r1(amu2,amu1,tmu2,tmu1,f2,alpha,beta,pi2,alpha2,rho) 
  AP_r2=SR_r2/power   
  result<-c(power, f1, AP_r1, SR_r1,f2, AP_r2, SR_r2) 
  names(result)<- c("power", "f1", "AP_r1", "SR_r1","f2", "AP_r2", "SR_r2") 
  return(result) 
} 
 
 
Three Regions: 
SRfun3_r1<-
function(amu1,amu2,amu3,tmu1,tmu2,tmu3,f1,f2,alpha,beta,pi1,alpha1,rho){   
  f3=1-f1-f2 
  zalpha=qnorm(1-alpha) 
  zbeta=qnorm(1-beta)   
  zalpha1=qnorm(1-alpha1)   
  amu=f1*amu1+f2*amu2+f3*amu3  
  tmu=f1*tmu1+f2*tmu2+f3*tmu3  
  c1=pi1/(1-pi1*f1)*sqrt(f1*(1-f1))    
  c2=(pi1*tmu-tmu1)/amu/(1-pi1*f1)*sqrt(f1*rho)*(zalpha+zbeta)+zalpha1/(1-
pi1*f1)*sqrt(1-2*pi1*f1+pi1**2*f1)     
  c3=sqrt(f1) 
  c4=sqrt(1-f1) 
  c5=(1-tmu/amu*sqrt(rho))*zalpha-tmu/amu*sqrt(rho)*zbeta   
  a1=(c2*c4+c1*c5)/(c4+c1*c3)   
  low1=c5/c4 
  low2=-c3/c4   
  if (c1==0){ 
    up1=Inf 
    up2=0 
  } 
  else { 
    up1=-c2/c1 
    up2=1/c1 
  }   
116 
 
 
  SR=APint(low1,low2,up1,up2,a1) 
  return(SR)  
} 
 
R3_AP<-
function(amu1,amu2,amu3,tmu1,tmu2,tmu3,f1,f2,alpha,beta,pi1,alpha1,pi2,alpha2,pi3,al
pha3,rho){   
  f3=1-f1-f2   
  amu=f1*amu1+f2*amu2+f3*amu3  
  tmu=f1*tmu1+f2*tmu2+f3*tmu3   
  zalpha=qnorm(1-alpha) 
  zbeta=qnorm(1-beta)     
  power=pnorm((tmu/amu*sqrt(rho)-1)*zalpha+tmu/amu*sqrt(rho)*zbeta)   
  SR_r1=SRfun3_r1(amu1,amu2,amu3,tmu1,tmu2,tmu3,f1,f2,alpha,beta,pi1,alpha1,rho) 
  AP_r1=SR_r1/power 
  SR_r2=SRfun3_r1(amu2,amu1,amu3,tmu2,tmu1,tmu3,f2,f1,alpha,beta,pi2,alpha2,rho) 
  AP_r2=SR_r2/power 
  SR_r3=SRfun3_r1(amu3,amu2,amu1,tmu3,tmu2,tmu1,f3,f2,alpha,beta,pi3,alpha3,rho) 
  AP_r3=SR_r3/power   
  result<-c(power, f1, AP_r1, SR_r1,f2, AP_r2, SR_r2,f3, AP_r3, SR_r3) 
  names(result)<- c("power", "f1", "AP_r1", "SR_r1","f2", "AP_r2", "SR_r2","f3", 
"AP_r3", "SR_r3") 
  return(result) 
} 
 
 
 R Functions for Calculation of Conditional Power, Conditional Assurance 
Probability and Conditional Success Rate 
Two Regions: 
cSRfun2_r1<-function(d11,d21,f11,f12,mu12,mu22,pi1,alpha2,rho,theta,sigma,N){ 
  f21=1-f11 
  f22=1-f12   
  zalpha2=qnorm(1-alpha2)  
  d1=d11*f11+d21*f21 
  mu2=mu12*f12+mu22*f22 
  z1=d1/sqrt(2*sigma**2/theta/N) 
  den=f12*rho*(1-theta)/(f11*theta+f12*rho*(1-theta))-pi1*f12*rho*(1-
theta)/(theta+rho*(1-theta)) 
  c1=pi1*rho*(1-theta)/(theta+rho*(1-theta))*sqrt((1-f12)*f12)/den 
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  c2=(pi1*(theta*d1+rho*(1-theta)*mu2)/(theta+rho*(1-theta))-
(f11*theta*d11+f12*rho*(1-theta)*mu12)/(f11*theta+f12*rho*(1-
theta)))/sqrt(2*sigma**2/(f12*rho*(1-theta)*N))/den 
  c3=sqrt(f12) 
  c4=sqrt(1-f12) 
  c5=sqrt(1/(1-theta))*zalpha2-sqrt(theta/(1-theta))*z1-mu2/sqrt(2*sigma**2/(rho*(1-
theta)*N)) 
  a1=(c2*c4+c1*c5)/(c4+c1*c3) 
  low1=c5/c4 
  low2=-c3/c4 
  if (c1==0){ 
    up1=Inf 
    up2=0 
  } 
  else { 
    up1=-c2/c1 
    up2=1/c1 
  } 
  AP=APint(low1,low2,up1,up2,a1) 
  return(AP)  
} 
 
R2_cAP<-function(d11,d21,f11,f12,mu12,mu22,pi1,pi2,alpha2,rho,theta,sigma,N){   
  f21=1-f11 
  f22=1-f12   
  zalpha2=qnorm(1-alpha2)   
  d1=d11*f11+d21*f21 
  mu2=mu12*f12+mu22*f22   
  z1=d1/sqrt(2*sigma**2/theta/N)   
  cpower=1-pnorm(sqrt(1/(1-theta))*zalpha2-sqrt(theta/(1-theta))*z1-
mu2/sqrt(2*sigma**2/(rho*(1-theta)*N)))   
  cSR_r1=cSRfun2_r1(d11,d21,f11,f12,mu12,mu22,pi1,alpha2,rho,theta,sigma,N) 
  cAP_r1=cSR_r1/cpower   
  cSR_r2=cSRfun2_r1(d21,d11,f21,f22,mu22,mu12,pi2,alpha2,rho,theta,sigma,N) 
  cAP_r2=cSR_r2/cpower   
  result<-c(cpower, f11, f12, cAP_r1, cSR_r1,f21, f22, cAP_r2, cSR_r2) 
  names(result)<- c("cpower", "f11","f12", "cAP_r1", "cSR_r1","f21","f22", "cAP_r2", 
"cSR_r2") 
  return(result) 
} 
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